INTRODUCTION {#s1}
============

Cervix cancer is caused by abnormal proliferation of cells with capacity of invasion, arising from the lower, narrow end of uterus to vagina. According to the definition of the National Cancer Institution of American National Institutes of Health, cervix cancer contains two main types, the squamous cell carcinoma originating from thin, flat cells that line the cervix and the adenocarcinoma arose from cells that make mucus and other fluids \[[@R1], [@R2]\]. And it is the second most frequent cancer occurred in female worldwide, next to breast cancer, accounting for 7.9% cancer cases and 7.5% cancer deaths in female in 2012 \[[@R3], [@R4]\]. With the development of medical and healthcare system, the average 5-year survival rate of cervical cancer has reached 66% in developed countries, yet less than half patients from developing countries could live longer than 5 years \[[@R5], [@R6]\]. The international biological study on etiology reported that human papillomavirus (HPV) was responsible for about 93% invasive cervical cancers \[[@R7]\]. Additionally, cigarette smoking, no matter active or passive, long-term use of oral contraceptives and multiple pregnancies are also high risk factors for cervix cancer \[[@R8], [@R9]\].

On the fundamental of clinical examination instead of the surgical findings, the International Federation of Gynecology and Obstetrics (FIGO) divides the cervix cancer into five stages from 0 stage to IV stage \[[@R10]\]. Surgery is a common treatment, while the specific operation and scope for different FIGO stages are distinctive. Except for conization and hysterectomy, one of the traditional surgeries usually performed on stage IA microinvasive cancer, there are many methods of fertility preservation for cervical cancer, as radical vaginal trachelectomy \[[@R11]\]. Besides, radiotherapy is also an available way to treat cervical cancer and preserve reproductive function, splitting into external and internal radiation therapy, which are given depending on both type and stage of the cancer \[[@R12]\].

For further improvement of survival length and decreasing the incidence of recurrence and distant metastasis, chemotherapy is often combined with radiotherapy after surgery through multiple mechanisms exerting the synergistic effect. Cisplatin, fluorouracil, hydroxyurea, bleomycin, ifosfamide and their combination with other drugs are common medical choices with different pharmacological reactions, and the combination of chemo and radiotherapy could be further categorized into neoadjuvant, adjuvant and concurrent therapy due to whether the medication was performed before, after or concurrent with the process of radiation \[[@R13]--[@R14]\].

Fortunately, regardless of the administration time point, a large number of randomized control trials (RCTs) assessing the efficacy and safety between different chemotherapeutic agents after radiotherapy or radiotherapy alone had been carried out and provided with sufficient clinical data. However, some of them were contradicted to each other. Two trials appraised the concurrent radiation and cisplatin plus fluorouracil compared with radiation alone. Morris et al. reported a significant superiority in both overall survival (OS) and recurrence-free survival (RFS), but the same outcomes of Kim et al.\'s trial were 1.03 and 1.01 without statistically significance. Meanwhile, although many meta-analyses (MA) existed, there was still a lack of a conclusive treatment strategy for patients with cervical cancer, and none of them conducted a network meta-analysis (NMA) among variety of chemotherapies to draw the best outcomes result in patients \[[@R15], [@R16]\].

As the first NMA on this subject, we synthesized both direct and indirect data to compare the efficacy among multiple common chemotherapies combined with radiotherapy in patients with cervical cancer after surgery. OS, RFS, the incidence of recurrence, and distant metastasis were used as the outcomes to assess cisplatin, cisplatin+fluorouracil, hydroxyurea, fluorouracil alone, cisplatin+ifosfamide, bleomycin+ifosfamide+cisplatin, mitomycin C+fluorouracil, and other 14 chemotherapeutic strategies. 5-year OS and PFS were considered as primary outcomes. This multiple-treatment Bayesian meta-analysis aimed to integrate the existed data and to draw a conclusion to offer a guideline for the corresponding clinical practice.

RESULTS {#s2}
=======

Included studies {#s2_1}
----------------

This NMA included 39 eligible trials with 8,952 patients involved, screened from the 412 identified literatures from electronic database depending on the inclusion and exclusion criteria, which were published between March 1979 and October 2015 were included \[[@R13], [@R14], [@R17]--[@R53]\], and the efficacy of a total of 22 chemotherapies were evaluated. Besides, 113 meta-analysis or systematic reviews were retrieved through the keywords searching on the Internet. The characteristics of patients, the details of the specific interventions and the analyzed outcomes of each trial were listed in Table [1](#T1){ref-type="table"}. Among 39 eligible trials, 34 of them gave the data of OS, 36 trials showed the PFS, 34 pairs of comparisons involved the data of recurrence, and the outcome of distant metastasis was analyzed in 24 trials. The directly compared connections among each chemotherapeutic agent for each outcome were displayed in Figure [1](#F1){ref-type="fig"}.

###### Baseline characteristics of included studies

  Study               Patient     Intervention   Outcome                                                                                                                                                     
  ------------------- ----------- -------------- --------- --------------- ---------- ------------------ ---- --------- -------------------------------------- --------------------------------- --- --- --- ----
  Pu 2013             China       √              60        140, 145        IB-IIA     45, 47             √    c         Cis vs Cis + Doc                       40, 30 + 30                       √   √   √   √
  Yin 2012            China       \-             120       148, 104        IB2-IIB    NA                 \-   n         Cis + Pac vs Nedaplatin + Pac          50 + 175, 50 + 175                √   √       
  Symonds 2000        UK          √              100       104, 100        IIB-IVA    49, 48             √    n, r      Cis + Methotrexate vs Placebo          50 + 100, -                       √   √   √   √
  Roberts 2000        USA         √              46        78, 82          IB2-IVA    47.5, 48.5         √    a, r      MitoC vs Placebo                       15, -                             √   √       
  Morris 1999         USA         √              60        195, 193        IB-IVA     47, 47             √    c, r      Cis + Flu vs Placebo                   75 + 4000, -                      √   √   √   
  Tseng 1997          China       √              60        60, 62          IIB/IIIB   NA                 √    c, r      Ble + Cis + Vcr vs Placebo             25 + 50 + 1, -                    √   √   √   √
  Thomas 1998         Canada      √              80        50, 49          IB-IVA     NA                 √    c, r      Flu vs Placebo                         1000, -                               √   √   
  Sundfor 1996        Norway      √              60        47, 47          IIIB/IVA   52.7, 52.5         √    n, r      Cis + Flu vs Placebo                   100 + 1000, -                     √   √   √   √
  Rose 1999           USA         √              48        176, 173, 177   IIB-IVA    NA                 √    c         Cis vs Cis + Flu + Hyd vs Hyd          40, 50 + 4000+ 2000, 3000         √   √   √   
  Keys 1999           USA         \-             48        183, 186        IB         NA                 √    c, r      Cis vs Placebo                         40, -                             √   √   √   √
  Long 2005           USA         √              36        147, 146        IVB        46, 48             √    c         Cis + Topotecan vs Cis                 50 + 0.75, 50                     √   √   √   
  Kim 2008            Korea       √              72        78, 77          IIB-IVA    58, 57             √    c         Cis + Flu vs Cis                       20 + 1000, 30                     √   √   √   √
  Lanciano 2005       USA         √              48        159, 157        IIB-IVA    NA                 √    c         Cis vs Flu                             40, 225                           √   √   √   √
  Peters 2000         USA         √              96        127, 116        IA2-IIA    41, 38             √    c, r      Cis + Flu vs Placebo                   70 + 1000, -                      √   √   √   √
  Whitney 1999        USA         √              72        177, 191        IIB-IVA    NA                 √    a         Cis + Flu vs Hyd                       50 + 4000, 3000                   √   √   √   √
  Eifel 2004          USA         √              96        195, 195        IIB-IVA    NA                 √    c, r      Cis + Flu vs Placebo                   75 + 4000, -                      √   √   √   √
  Eddy 2007           USA         √              72        145, 143        IB         NA                 √    n, r      Cis + Vcr vs Placebo                   50 + 1, -                         √   √   √   √
  Herod 2000          UK          √              84        89, 88          IB-IVA     47, 46             √    n, r      Ble + Cis + Ifo vs Placebo             30 + 50 + 5000, -                 √       √   
  Lorvidhaya 2003     Thailand    √              120       233, 221, 242   IIB-IVA    48, 49, 50         √    c, a, r   Flu + MitoC vs Flu vs Placebo          300 mg/d + 10, 200 mg/d, -        √   √   √   √
  Buda 2005           Italy       √              60        96, 108         IB2-IVA    47, 49             \-   n         Cis + Ifo + Pac vs Cis + Ifo           75 + 5000+ 175, 75 + 5000         √   √   √   \*
  Leborgne 1997       Uruguay     √              60        48, 49          IB-IVA     47, 43             √    a, r      Ble + Cis + Vcr vs Placebo             25 + 50 + 1, -                        √   √   
  Nedovic 2012        Serbia      \-             42        64, 70          IIB-IVA    51, 54             √    c         Cis + Flu vs Cis                       75 + 4000, 40                     √   √   √   √
  Garipagaoglu 2004   Turkey      √              60        22, 22          IIB/IIIB   50.5, 49.2         √    c, r      Cis vs Placebo                         20, -                             √   √   √   √
  Moore 2004          USA         \-             24        130, 134        IVB        48.5, 46           \-   n         Cis + Pac vs Cis                       50 + 135, 50                      √   √       √
  Omura 1997          USA         √              24        151, 147, 140   IVB        46.3, 48.8, 47.3   \-   n         Cis + Ifo vs Cis + Mitolactol vs Cis   50 + 5000, 50 + 180, 50           √   √   √   
  Pearcey 2002        Canada      √              120       127, 126        IIB-IVA    NA                 √    c, r      Cis vs Placebo                         40, -                             √   √   √   √
  Bloss 2002          USA         √              24        141, 146        IVB        46, 45             \-   n         Ble + Cis + Ifo vs Cis + Ifo           30 units + 50 + 5000, 50 + 5000   √   √   √   
  Tattersall 1992     Australia   √              75        34, 37          IIB-IVA    54, 56             √    c, r      Ble + Cis + Vbl vs Placebo             15 + 50 + 4, -                    √   √   √   √
  Tattersall 1991     Australia   √              72        34, 37          IB-IIA     NA                 √    a, r      Ble + Cis + Vbl vs Placebo             15 + 50 + 4, -                        √   √   √
  Tattersall 1995     Australia   √              48        129, 131        IIB-IVA    47, 52             √    c, r      Cis + Epi vs Placebo                   60 + 110, -                       √   √   √   √
  Wong 1988           China       √              70        22, 25          IIB-IIIB   NA                 √    c, r      Cis vs Placebo                         25, -                                 √   √   √
  Wong 1999           China       √              140       110, 110        I-IIIB     52.4, 55.5         √    a, r      Epi vs Placebo                         90, -                             √   √   √   √
  Tabata 2003         Japan       √              60        32, 29          IIIB/IVA   57, 59             √    a, r      Ble + Cis + MitoC + Vbl vs Placebo     3 + 10+ 7 + 0.7, -                √       √   √
  Piver 1987          USA         √              156       20, 25          IIIB       NA                 √    c, r      Hyd vs Placebo                         80 mg/kg, -                       √   √   √   
  Piver 1983          USA         √              110       20, 20          IIB        45.7, 50.5         √    c, r      Hyd vs Placebo                         80 mg/kg, -                       √       √   
  Nagai 2001          Japan       √              120       32, 28          II-IV      55.6, 64.4         √    a         Cis vs Flu                             120 mg, 200 mg/d                  √   √       
  Kumar 1994          India       √              24        94, 90          IIB-IVA    45, 45.5           √    n, r      Ble + Cis + Ifo vs Placebo             15 + 50 + 1000, -                     √   √   √
  Hreshchyshyn 1979   USA         \-             48        51, 46          IIB-IVA    NA                 √    c, r      Hyd vs Placebo                         80 mg/kg, -                       √   √   √   
  Donnelly 2015       USA         \-             348       42, 95, 99      IB1-IVA    49 (23-83)         √    c, c, r   Cis + Flu vs Cis vs Placebo            70 + 1000, 40, -                  √   √       

Note: FIGO, International Federation of Gynecology and Obstetrics; RT, radiationtherapy; OS, overall survival; RFS, recurrence-free survival; a, adjuvant; n, neoadjuvant; c, concurrent; r, radiotherapy only.

\*Data excluded to achieve network connectivity.

![Network plots for each outcome\
**(A)** recurrence; **(B)** distant metastasis; **(C)** 1-year and 3-year overall survival (OS) and recurrence-free survival (RFS); **(D)** 5-year OS and RFS. Each circle represents a specific treatment, and the size of the circles depends on the sample size involved in a specific treatment. The width of the line depends on the number of included studies for each comparison. OS, overall survival; RFS, recurrence-free survival.](oncotarget-08-49515-g001){#F1}

Overall survival (OS) {#s2_2}
---------------------

OS were treated as the primary outcomes. Since 1-year OS was a short-term evaluation index showing no significant difference in most cases (Table [2](#T2){ref-type="table"}), 3-year and 5-year OS were more reliable to reflect their efficacies. The hazard ratio (HR) of placebo was compared with 22 chemotherapies reported the HR of 3-year OS. As shown in the lower panel of Table [3](#T3){ref-type="table"}, cisplatin+ifosfamide+paclitaxel (HR = 2.14, 95% CrI: 1.1-4.17), cisplatin+fluorouracil+hydroxyurea (HR = 1.78, 95% CrI: 1.08- 2.93), cisplatin+paclitaxel (HR = 1.77, 95% CrI: 1.23-2.54), fluorouracil+mitomycin C (HR = 1.75, 95% CrI: 1.04-2.95), cisplatin+ifosfamide (HR = 1.71, 95% CrI: 1.26-2.33), cisplatin+mitolactol (HR = 1.57, 95% CrI: 1.11-2.23), cisplatin+topotecan (HR = 0.69, 95% CrI: 0.50-0.96), cisplatin (HR = 0.70, 95% CrI: 0.56-0.87), and cisplatin+fluorouracil (HR = 1.32, 95% CrI: 1.07-1.64), these nine interventions with 95% CrI excluded 1.00 had dramatic advantage on improving the survival length of patients. Furthermore, for 5-year OS in the lower panel of Table [4](#T4){ref-type="table"}, cisplatin+docetaxel (HR = 2.22, 95% CrI: 1.27-3.87), cisplatin+fluorouracil+hydroxyurea (HR = 1.81, 95% CrI: 1.15-2.86), fluorouracil+mitomycin C (HR =1.67, 95% CrI: 1.02-2.71), cisplatin (HR = 1.44, 95% CrI: 1.15-1.8), and cisplatin+fluorouracil (HR = 1.29, 95% CrI: 1.05-1.59) had statistically significance compared with placebo. Results of ranking analysis in Table [5](#T5){ref-type="table"} suggested that cisplatin+fluorouracil+hydroxyurea was efficacious in 1-year and 5-year period. Another two favorable interventions in 5-year OS were cisplatin+docetaxel and fluorouracil+mitomycin C, suggested a good therapeutic effect in long-term survival.

###### Mixed evidence of 1-year overall survival and recurrence-free survival for different treatments

                                                      1-year RFS                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  ----------------------------- --------------------- ----------------------------- --------------------- --------------------- ------------------- ------------------- ------------------- ------------------- --------------------- ------------------- --------------------- -------------------------- ------------------------ ------------------- ----------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ---------------------- -------------------
  **1-year OS**                 **Ble + Cis + Ifo**   **Ble + Cis + Ifo**                                 1.11 (0.46, 2.69)     1.53 (0.61, 3.85)   1.09 (0.6, 1.96)    1.6 (0.34, 7.59)    1.92 (0.66, 5.53)   0.96 (0.5, 1.86)      0.98 (0.28, 3.36)   0.97 (0.59, 1.57)     1 (0.35, 2.87)             1.32 (0.54, 3.19)        1.23 (0.57, 2.64)   1.12 (0.49, 2.57)       1.21 (0.55, 2.62)   1.59 (0.56, 4.52)   1.09 (0.46, 2.54)   1.36 (0.64, 2.89)   1.2 (0.4, 3.63)     1.09 (0.51, 2.29)   0.97 (0.37, 2.54)      1.43 (0.78, 2.62)
  **Ble + Cis + MitoC + Vbl**   0.67 (0.2, 2.22)      **Ble + Cis + MitoC + Vbl**                                                                                                                                                                                                                                                                                                                                                                                                                                              
  **Ble + Cis + Vbl**           0.88 (0.26, 2.95)     1.31 (0.34, 4.95)             **Ble + Cis + Vbl**   1.38 (0.53, 3.56)     0.98 (0.48, 2)      1.44 (0.29, 7.19)   1.72 (0.58, 5.1)    0.86 (0.42, 1.77)   0.88 (0.25, 3.13)     0.87 (0.38, 2)      0.9 (0.25, 3.15)      1.18 (0.47, 2.96)          1.1 (0.46, 2.63)         1.01 (0.4, 2.54)    1.08 (0.45, 2.61)       1.43 (0.49, 4.17)   0.98 (0.4, 2.36)    1.23 (0.54, 2.79)   1.08 (0.35, 3.35)   0.98 (0.44, 2.18)   0.87 (0.33, 2.35)   1.29 (0.67, 2.46)      
  **Ble + Cis + Vcr**           1.26 (0.26, 6.13)     1.87 (0.35, 10.02)            1.43 (0.27, 7.75)     **Ble + Cis + Vcr**   0.71 (0.33, 1.52)   1.04 (0.2, 5.33)    1.25 (0.41, 3.82)   0.63 (0.29, 1.34)   0.64 (0.17, 2.33)     0.63 (0.26, 1.51)   0.65 (0.18, 2.34)     0.86 (0.33, 2.22)          0.8 (0.32, 1.98)         0.73 (0.28, 1.91)   0.79 (0.32, 1.96)       1.04 (0.34, 3.12)   0.71 (0.28, 1.78)   0.89 (0.38, 2.11)   0.78 (0.25, 2.5)    0.71 (0.31, 1.65)   0.63 (0.23, 1.76)   0.93 (0.47, 1.87)      
  **Cis**                       0.88 (0.41, 1.88)     1.3 (0.48, 3.53)              1 (0.36, 2.75)        0.7 (0.17, 2.92)      **Cis**             1.47 (0.35, 6.22)   1.76 (0.7, 4.45)    0.88 (0.6, 1.3)     0.9 (0.3, 2.73)       0.89 (0.56, 1.42)   0.92 (0.32, 2.62)     1.21 (0.59, 2.48)          1.13 (0.7, 1.84)         1.03 (0.57, 1.85)   1.11 (0.67, 1.84)       1.46 (0.59, 3.62)   1 (0.51, 1.96)      1.26 (0.76, 2.08)   1.11 (0.42, 2.94)   1 (0.6, 1.67)       0.9 (0.4, 2.01)     1.32 (0.97, 1.79)      
  **Cis + Doc**                 1.02 (0.18, 5.72)     1.51 (0.24, 9.52)             1.16 (0.18, 7.35)     0.81 (0.1, 6.66)      1.16 (0.25, 5.45)   **Cis + Doc**       1.2 (0.22, 6.65)    0.6 (0.14, 2.67)    0.61 (0.1, 3.77)      0.61 (0.13, 2.76)   0.62 (0.1, 3.71)      0.82 (0.16, 4.12)          0.77 (0.17, 3.52)        0.7 (0.15, 3.32)    0.75 (0.16, 3.48)       0.99 (0.18, 5.46)   0.68 (0.14, 3.34)   0.85 (0.19, 3.93)   0.75 (0.13, 4.29)   0.68 (0.15, 3.14)   0.61 (0.12, 3.18)   0.9 (0.2, 3.91)        
  **Cis + Epi**                 0.83 (0.26, 2.58)     1.23 (0.34, 4.36)             0.94 (0.26, 3.39)     0.65 (0.13, 3.36)     0.94 (0.37, 2.38)   0.81 (0.13, 4.91)   **Cis + Epi**       0.5 (0.2, 1.26)     0.51 (0.13, 2.06)     0.5 (0.18, 1.4)     0.52 (0.13, 2.08)     0.69 (0.23, 2.03)          0.64 (0.23, 1.82)        0.58 (0.2, 1.74)    0.63 (0.22, 1.8)        0.83 (0.24, 2.8)    0.57 (0.2, 1.63)    0.71 (0.26, 1.95)   0.63 (0.18, 2.24)   0.57 (0.21, 1.53)   0.51 (0.16, 1.6)    0.75 (0.31, 1.78)      
  **Cis + Flu**                 0.93 (0.41, 2.11)     1.39 (0.51, 3.78)             1.06 (0.38, 2.95)     0.74 (0.18, 3.12)     1.06 (0.69, 1.64)   0.92 (0.18, 4.55)   1.13 (0.44, 2.89)   **Cis + Flu**       1.02 (0.34, 3.09)     1.01 (0.56, 1.8)    1.04 (0.34, 3.14)     1.37 (0.67, 2.81)          1.28 (0.69, 2.38)        1.17 (0.58, 2.35)   1.26 (0.67, 2.37)       1.65 (0.67, 4.1)    1.13 (0.58, 2.22)   1.42 (0.8, 2.52)    1.25 (0.47, 3.33)   1.13 (0.68, 1.89)   1.01 (0.45, 2.27)   **1.49 (1.1, 2.03)**   
  **Cis + Flu + Hyd**           0.69 (0.19, 2.51)     1.02 (0.25, 4.22)             0.78 (0.19, 3.27)     0.54 (0.09, 3.15)     0.78 (0.26, 2.35)   0.67 (0.1, 4.48)    0.83 (0.21, 3.29)   0.74 (0.24, 2.22)   **Cis + Flu + Hyd**   0.99 (0.3, 3.26)    1.02 (0.22, 4.66)     1.35 (0.38, 4.79)          1.26 (0.37, 4.22)        1.15 (0.33, 4.02)   1.23 (0.36, 4.18)       1.62 (0.41, 6.49)   1.11 (0.32, 3.86)   1.4 (0.42, 4.6)     1.23 (0.29, 5.15)   1.11 (0.42, 2.97)   1 (0.27, 3.73)      1.46 (0.49, 4.36)      
  **Cis + Ifo**                 0.79 (0.4, 1.58)      1.17 (0.36, 3.84)             0.9 (0.27, 2.98)      0.63 (0.13, 3.02)     0.9 (0.45, 1.81)    0.77 (0.14, 4.22)   0.96 (0.31, 2.96)   0.85 (0.38, 1.86)   1.15 (0.32, 4.15)     **Cis + Ifo**       1.03 (0.4, 2.64)      1.36 (0.59, 3.13)          1.27 (0.65, 2.49)        1.16 (0.55, 2.45)   1.25 (0.63, 2.48)       1.64 (0.6, 4.48)    1.12 (0.51, 2.5)    1.41 (0.72, 2.77)   1.24 (0.43, 3.61)   1.12 (0.57, 2.21)   1.01 (0.4, 2.51)    1.48 (0.87, 2.51)      
  **Cis + Ifo + Pac**           0.8 (0.25, 2.53)      1.18 (0.26, 5.32)             0.91 (0.2, 4.12)      0.63 (0.1, 3.91)      0.91 (0.29, 2.89)   0.78 (0.11, 5.39)   0.97 (0.22, 4.16)   0.85 (0.25, 2.88)   1.16 (0.24, 5.64)     1.01 (0.4, 2.54)    **Cis + Ifo + Pac**   1.32 (0.38, 4.64)          1.23 (0.39, 3.92)        1.12 (0.34, 3.74)   1.21 (0.38, 3.88)       1.59 (0.4, 6.3)     1.09 (0.32, 3.74)   1.37 (0.43, 4.36)   1.21 (0.29, 5)      1.09 (0.34, 3.47)   0.98 (0.26, 3.62)   1.44 (0.49, 4.22)      
  **Cis + Metho- trexate**      1 (0.35, 2.85)        1.48 (0.45, 4.86)             1.14 (0.34, 3.78)     0.79 (0.16, 3.82)     1.14 (0.51, 2.57)   0.98 (0.17, 5.61)   1.21 (0.39, 3.75)   1.07 (0.47, 2.44)   1.46 (0.4, 5.33)      1.27 (0.45, 3.57)   1.25 (0.31, 5.02)     **Cis + Metho- trexate**   0.93 (0.39, 2.22)        0.85 (0.34, 2.15)   0.92 (0.38, 2.2)        1.21 (0.41, 3.52)   0.83 (0.34, 1.99)   1.04 (0.46, 2.36)   0.91 (0.29, 2.83)   0.83 (0.37, 1.84)   0.74 (0.28, 1.98)   1.09 (0.57, 2.08)      
  **Cis + Mito- lactol**        1.01 (0.34, 3.03)     1.5 (0.42, 5.34)              1.15 (0.32, 4.14)     0.8 (0.16, 4.11)      1.15 (0.52, 2.53)   0.99 (0.17, 5.6)    1.22 (0.36, 4.14)   1.08 (0.44, 2.66)   1.47 (0.38, 5.69)     1.28 (0.44, 3.67)   1.27 (0.31, 5.14)     1.01 (0.33, 3.13)          **Cis + Mito- lactol**   0.91 (0.43, 1.95)   0.98 (0.49, 1.98)       1.29 (0.46, 3.62)   0.89 (0.39, 2.03)   1.11 (0.55, 2.24)   0.98 (0.33, 2.92)   0.88 (0.44, 1.8)    0.79 (0.31, 2.03)   1.17 (0.66, 2.07)      
  **Cis + Pac**                 1.05 (0.44, 2.55)     1.56 (0.52, 4.66)             1.2 (0.39, 3.63)      0.83 (0.19, 3.75)     1.2 (0.77, 1.88)    1.03 (0.21, 5.16)   1.28 (0.45, 3.58)   1.13 (0.6, 2.11)    1.53 (0.47, 5.04)     1.33 (0.58, 3.06)   1.32 (0.38, 4.57)     1.05 (0.42, 2.67)          1.04 (0.42, 2.59)        **Cis + Pac**       1.08 (0.5, 2.34)        1.42 (0.48, 4.18)   0.97 (0.4, 2.37)    1.22 (0.56, 2.64)   1.07 (0.34, 3.36)   0.97 (0.44, 2.12)   0.87 (0.32, 2.36)   1.28 (0.66, 2.48)      
  **Cis + Topo- tecan**         1.03 (0.36, 2.93)     1.52 (0.45, 5.2)              1.17 (0.34, 4.04)     0.81 (0.16, 4.05)     1.17 (0.57, 2.4)    1.01 (0.18, 5.52)   1.24 (0.38, 4.02)   1.1 (0.48, 2.54)    1.5 (0.4, 5.56)       1.3 (0.48, 3.54)    1.29 (0.33, 5.02)     1.03 (0.35, 3.04)          1.02 (0.35, 2.95)        0.97 (0.42, 2.27)   **Cis + Topo- tecan**   1.32 (0.47, 3.72)   0.9 (0.39, 2.09)    1.13 (0.55, 2.31)   1 (0.33, 2.99)      0.9 (0.44, 1.85)    0.81 (0.31, 2.09)   1.19 (0.66, 2.14)      
  **Cis + Vcr**                 0.95 (0.27, 3.27)     1.4 (0.36, 5.47)              1.07 (0.27, 4.24)     0.75 (0.14, 4.13)     1.08 (0.38, 3.08)   0.93 (0.14, 6)      1.14 (0.31, 4.25)   1.01 (0.35, 2.91)   1.38 (0.32, 5.92)     1.2 (0.35, 4.1)     1.18 (0.25, 5.52)     0.95 (0.28, 3.24)          0.94 (0.25, 3.48)        0.9 (0.29, 2.81)    0.92 (0.26, 3.28)       **Cis + Vcr**       0.68 (0.24, 1.94)   0.86 (0.32, 2.32)   0.76 (0.21, 2.67)   0.68 (0.26, 1.81)   0.61 (0.2, 1.9)     0.9 (0.38, 2.11)       
  **Epi**                       0.87 (0.21, 3.68)     1.29 (0.27, 6.07)             0.99 (0.21, 4.7)      0.69 (0.11, 4.43)     0.99 (0.27, 3.57)   0.85 (0.11, 6.34)   1.05 (0.23, 4.74)   0.93 (0.26, 3.38)   1.27 (0.25, 6.49)     1.1 (0.26, 4.63)    1.09 (0.2, 6)         0.87 (0.21, 3.66)          0.86 (0.19, 3.89)        0.83 (0.21, 3.22)   0.85 (0.19, 3.68)       0.92 (0.19, 4.48)   **Epi**             1.26 (0.57, 2.75)   1.11 (0.37, 3.33)   1 (0.47, 2.14)      0.89 (0.34, 2.33)   1.32 (0.72, 2.39)      
  **Flu**                       1.18 (0.47, 2.97)     1.75 (0.58, 5.3)              1.34 (0.44, 4.13)     0.94 (0.21, 4.25)     1.35 (0.77, 2.36)   1.16 (0.22, 5.99)   1.43 (0.5, 4.08)    1.26 (0.65, 2.47)   1.72 (0.51, 5.77)     1.49 (0.62, 3.62)   1.48 (0.41, 5.31)     1.18 (0.46, 3.04)          1.17 (0.44, 3.08)        1.12 (0.55, 2.31)   1.15 (0.46, 2.86)       1.25 (0.39, 3.97)   1.36 (0.34, 5.35)   **Flu**             0.88 (0.31, 2.53)   0.8 (0.41, 1.56)    0.71 (0.29, 1.75)   1.05 (0.63, 1.74)      
  **Flu + MitoC**               0.98 (0.29, 3.31)     1.45 (0.38, 5.55)             1.11 (0.29, 4.31)     0.77 (0.14, 4.21)     1.11 (0.4, 3.11)    0.96 (0.15, 6.12)   1.18 (0.33, 4.31)   1.05 (0.37, 2.94)   1.42 (0.34, 6.02)     1.24 (0.37, 4.16)   1.23 (0.27, 5.62)     0.98 (0.29, 3.29)          0.97 (0.27, 3.53)        0.93 (0.3, 2.85)    0.95 (0.27, 3.33)       1.03 (0.26, 4.12)   1.12 (0.23, 5.39)   0.83 (0.27, 2.57)   **Flu + MitoC**     0.9 (0.32, 2.56)    0.81 (0.25, 2.66)   1.19 (0.47, 3.01)      
  **Hyd**                       0.76 (0.33, 1.78)     1.13 (0.41, 3.16)             0.87 (0.31, 2.46)     0.6 (0.14, 2.59)      0.87 (0.53, 1.43)   0.75 (0.15, 3.78)   0.92 (0.35, 2.41)   0.82 (0.49, 1.35)   1.11 (0.42, 2.97)     0.97 (0.42, 2.2)    0.96 (0.28, 3.29)     0.76 (0.33, 1.78)          0.76 (0.3, 1.92)         0.72 (0.37, 1.41)   0.74 (0.31, 1.77)       0.81 (0.27, 2.37)   0.88 (0.24, 3.24)   0.65 (0.32, 1.31)   0.78 (0.27, 2.24)   **Hyd**             0.9 (0.37, 2.17)    1.32 (0.82, 2.12)      
  **MitoC**                     0.84 (0.26, 2.68)     1.24 (0.34, 4.52)             0.95 (0.26, 3.51)     0.66 (0.13, 3.46)     0.95 (0.37, 2.49)   0.82 (0.13, 5.05)   1.01 (0.29, 3.5)    0.9 (0.34, 2.36)    1.22 (0.3, 4.91)      1.06 (0.33, 3.36)   1.05 (0.24, 4.6)      0.84 (0.26, 2.66)          0.83 (0.24, 2.87)        0.79 (0.28, 2.29)   0.81 (0.25, 2.7)        0.89 (0.23, 3.36)   0.96 (0.21, 4.42)   0.71 (0.24, 2.07)   0.86 (0.23, 3.19)   1.1 (0.41, 2.95)    **MitoC**           1.47 (0.7, 3.1)        
  **Placebo**                   1.09 (0.52, 2.29)     1.61 (0.63, 4.1)              1.23 (0.48, 3.2)      0.86 (0.21, 3.46)     1.24 (0.87, 1.76)   1.06 (0.22, 5.19)   1.32 (0.56, 3.11)   1.16 (0.8, 1.68)    1.58 (0.54, 4.62)     1.38 (0.66, 2.86)   1.36 (0.42, 4.42)     1.09 (0.52, 2.26)          1.08 (0.45, 2.55)        1.03 (0.58, 1.82)   1.06 (0.48, 2.35)       1.15 (0.43, 3.09)   1.25 (0.36, 4.3)    0.92 (0.51, 1.67)   1.11 (0.42, 2.91)   1.42 (0.93, 2.18)   1.3 (0.53, 3.17)    **Placebo**            

###### Mixed evidence of 3-year overall survival and recurrence-free survival for different treatments

                                                3-year RFS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  --------------- ----------------------------- ----------------------- ----------------------------- --------------------- ----------------------- ----------------------- -------------------- ----------------------- ----------------------- ----------------------- ----------------------- ----------------------- -------------------------- ------------------------ ----------------------- ----------------------- -------------------- -------------------- ----------------------- ----------------------- ----------------------- ----------------------- ---------------------- -----------------------
  **3-year OS**   **Ble + Cis + Ifo**           **Ble + Cis + Ifo**                                   1.57 (0.78, 3.18)     1.66 (0.9, 3.05)        **1.47 (1.04, 2.09)**   1.29 (0.47, 3.55)    **2.39 (1.28, 4.47)**   1.32 (0.88, 1.98)       1.17 (0.63, 2.19)       1.04 (0.8, 1.34)        0.98 (0.54, 1.81)       1.57 (0.88, 2.78)          **2.24 (1.47, 3.4)**     1.16 (0.71, 1.92)       1.19 (0.74, 1.92)       1.89 (0.98, 3.65)    1.38 (0.66, 2.88)    **1.67 (1.08, 2.6)**    1.26 (0.74, 2.16)       **1.77 (1.14, 2.77)**   0.96 (0.47, 1.93)       3.06 (0.31, 30.58)     **1.91 (1.31, 2.8)**
                  **Ble + Cis + MitoC + Vbl**   0.77 (0.31, 1.91)       **Ble + Cis + MitoC + Vbl**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                  **Ble + Cis + Vbl**           1.3 (0.54, 3.13)        1.7 (0.53, 5.45)              **Ble + Cis + Vbl**   1.05 (0.49, 2.26)       0.94 (0.5, 1.76)        0.82 (0.26, 2.57)    1.52 (0.7, 3.29)        0.84 (0.45, 1.57)       0.75 (0.34, 1.65)       0.66 (0.34, 1.3)        0.63 (0.26, 1.5)        1 (0.48, 2.07)             1.42 (0.73, 2.78)        0.74 (0.36, 1.52)       0.76 (0.37, 1.54)       1.2 (0.54, 2.68)     0.88 (0.37, 2.09)    1.06 (0.56, 2.04)       0.8 (0.4, 1.62)         1.13 (0.58, 2.18)       0.61 (0.26, 1.4)        1.95 (0.18, 20.63)     1.22 (0.67, 2.2)
                  **Ble + Cis + Vcr**           2.99 (0.78, 11.5)       3.9 (0.83, 18.39)             2.3 (0.5, 10.6)       **Ble + Cis + Vcr**     0.89 (0.53, 1.5)        0.78 (0.26, 2.3)     1.44 (0.72, 2.87)       0.8 (0.47, 1.34)        0.71 (0.35, 1.44)       0.62 (0.35, 1.11)       0.59 (0.27, 1.32)       0.95 (0.5, 1.8)            1.35 (0.76, 2.39)        0.7 (0.37, 1.32)        0.72 (0.39, 1.33)       1.14 (0.56, 2.34)    0.83 (0.38, 1.84)    1.01 (0.58, 1.75)       0.76 (0.41, 1.4)        1.07 (0.61, 1.87)       0.58 (0.27, 1.23)       1.85 (0.18, 19.05)     1.15 (0.72, 1.86)
                  **Cis**                       0.85 (0.61, 1.18)       1.11 (0.46, 2.65)             0.65 (0.28, 1.5)      0.28 (0.08, 1.06)       **Cis**                 0.88 (0.34, 2.27)    1.62 (0.95, 2.78)       0.9 (0.71, 1.13)        0.8 (0.47, 1.35)        **0.7 (0.54, 0.92)**    0.67 (0.36, 1.23)       1.07 (0.66, 1.71)          1.52 (1.21, 1.91)        0.79 (0.55, 1.13)       0.81 (0.59, 1.12)       1.29 (0.72, 2.28)    0.94 (0.48, 1.82)    1.14 (0.85, 1.52)       0.86 (0.56, 1.32)       1.21 (0.9, 1.62)        0.65 (0.35, 1.21)       2.08 (0.21, 20.22)     **1.3 (1.05, 1.6)**
                  **Cis + Doc**                 0.79 (0.31, 1.98)       1.03 (0.3, 3.49)              0.6 (0.18, 2)         0.26 (0.05, 1.27)       0.93 (0.39, 2.18)       **Cis + Doc**        1.85 (0.62, 5.52)       1.02 (0.38, 2.71)       0.91 (0.31, 2.69)       0.8 (0.3, 2.15)         0.76 (0.25, 2.36)       1.21 (0.42, 3.51)          1.73 (0.65, 4.6)         0.9 (0.33, 2.48)        0.92 (0.34, 2.52)       1.47 (0.48, 4.45)    1.07 (0.33, 3.4)     1.3 (0.48, 3.5)         0.98 (0.34, 2.78)       1.37 (0.51, 3.71)       0.74 (0.24, 2.31)       2.37 (0.2, 27.89)      1.48 (0.56, 3.92)
                  **Cis + Epi**                 1.23 (0.67, 2.26)       1.6 (0.6, 4.28)               0.94 (0.37, 2.44)     0.41 (0.1, 1.65)        1.45 (0.84, 2.49)       1.56 (0.56, 4.32)    **Cis + Epi**           **0.55 (0.32, 0.94)**   0.49 (0.24, 1.01)       **0.43 (0.24, 0.78)**   **0.41 (0.18, 0.92)**   0.66 (0.34, 1.26)          0.94 (0.52, 1.68)        **0.49 (0.26, 0.93)**   **0.5 (0.27, 0.94)**    0.79 (0.38, 1.64)    0.58 (0.26, 1.29)    0.7 (0.4, 1.23)         **0.53 (0.28, 0.99)**   0.74 (0.42, 1.32)       **0.4 (0.19, 0.86)**    1.28 (0.12, 13.26)     0.8 (0.49, 1.31)
                  **Cis + Flu**                 0.92 (0.62, 1.36)       1.2 (0.5, 2.87)               0.71 (0.31, 1.63)     0.31 (0.08, 1.15)       1.08 (0.84, 1.4)        1.17 (0.48, 2.87)    0.75 (0.43, 1.29)       **Cis + Flu**           0.89 (0.53, 1.5)        0.79 (0.56, 1.11)       0.75 (0.39, 1.43)       1.19 (0.74, 1.91)          **1.7 (1.22, 2.35)**     0.88 (0.58, 1.35)       0.9 (0.61, 1.35)        1.44 (0.81, 2.55)    1.04 (0.54, 2.04)    1.27 (0.92, 1.75)       0.96 (0.62, 1.48)       **1.35 (1.01, 1.79)**   0.73 (0.39, 1.36)       2.32 (0.24, 22.86)     **1.45 (1.18, 1.79)**
                  **Cis + Flu + Hyd**           0.68 (0.38, 1.24)       0.89 (0.33, 2.38)             0.53 (0.2, 1.36)      **0.23 (0.06, 0.92)**   0.81 (0.48, 1.34)       0.87 (0.32, 2.36)    0.56 (0.27, 1.13)       0.74 (0.45, 1.23)       **Cis + Flu + Hyd**     0.88 (0.49, 1.6)        0.84 (0.37, 1.88)       1.34 (0.68, 2.64)          **1.91 (1.07, 3.41)**    0.99 (0.52, 1.88)       1.02 (0.55, 1.9)        1.62 (0.76, 3.43)    1.18 (0.52, 2.68)    1.43 (0.8, 2.55)        1.08 (0.56, 2.07)       1.52 (0.97, 2.36)       0.82 (0.37, 1.8)        2.61 (0.25, 27.03)     1.63 (0.96, 2.77)
                  **Cis + Ifo**                 **0.71 (0.54, 0.93)**   0.93 (0.38, 2.28)             0.55 (0.23, 1.29)     **0.24 (0.06, 0.9)**    0.84 (0.65, 1.08)       0.9 (0.37, 2.21)     0.58 (0.32, 1.04)       0.77 (0.55, 1.09)       1.04 (0.59, 1.82)       **Cis + Ifo**           0.95 (0.55, 1.65)       1.51 (0.88, 2.59)          **2.16 (1.52, 3.08)**    1.12 (0.72, 1.75)       1.15 (0.75, 1.76)       1.83 (0.98, 3.42)    1.33 (0.65, 2.71)    **1.62 (1.09, 2.38)**   1.22 (0.74, 2.01)       **1.71 (1.16, 2.53)**   0.92 (0.47, 1.81)       2.95 (0.3, 29.2)       **1.85 (1.33, 2.56)**
                  **Cis + Ifo + Pac**           0.57 (0.3, 1.09)        0.74 (0.25, 2.18)             0.44 (0.15, 1.24)     **0.19 (0.04, 0.82)**   0.67 (0.35, 1.28)       0.72 (0.25, 2.12)    0.46 (0.2, 1.07)        0.62 (0.31, 1.23)       0.83 (0.37, 1.88)       0.8 (0.44, 1.45)        **Cis + Ifo + Pac**     1.59 (0.74, 3.44)          **2.27 (1.18, 4.37)**    1.18 (0.58, 2.4)        1.21 (0.61, 2.42)       1.92 (0.84, 4.42)    1.4 (0.57, 3.44)     1.7 (0.87, 3.33)        1.28 (0.61, 2.69)       1.8 (0.92, 3.54)        0.97 (0.41, 2.32)       3.11 (0.29, 32.8)      **1.94 (1.03, 3.68)**
                  **Cis + Metho- trexate**      1.06 (0.6, 1.87)        1.38 (0.53, 3.59)             0.81 (0.32, 2.04)     0.35 (0.09, 1.4)        1.25 (0.76, 2.05)       1.35 (0.5, 3.63)     0.86 (0.44, 1.69)       1.15 (0.7, 1.89)        1.55 (0.79, 3.03)       1.49 (0.86, 2.56)       1.86 (0.83, 4.16)       **Cis + Metho- trexate**   1.43 (0.84, 2.42)        0.74 (0.41, 1.34)       0.76 (0.43, 1.35)       1.21 (0.61, 2.39)    0.88 (0.41, 1.89)    1.07 (0.64, 1.77)       0.8 (0.45, 1.43)        1.13 (0.68, 1.89)       0.61 (0.29, 1.26)       1.95 (0.19, 19.94)     1.22 (0.8, 1.87)
                  **Cis + Mito- lactol**        0.77 (0.5, 1.19)        1.01 (0.4, 2.52)              0.59 (0.25, 1.43)     **0.26 (0.07, 0.99)**   0.91 (0.69, 1.2)        0.98 (0.4, 2.42)     0.63 (0.34, 1.16)       0.84 (0.58, 1.23)       1.13 (0.63, 2.02)       1.09 (0.75, 1.58)       1.36 (0.67, 2.74)       0.73 (0.41, 1.29)          **Cis + Mito- lactol**   **0.52 (0.34, 0.79)**   **0.53 (0.36, 0.79)**   0.85 (0.46, 1.57)    0.62 (0.3, 1.25)     0.75 (0.52, 1.08)       **0.56 (0.35, 0.92)**   0.79 (0.55, 1.15)       **0.43 (0.22, 0.83)**   1.37 (0.14, 13.46)     0.85 (0.63, 1.16)
                  **Cis + Pac**                 0.69 (0.44, 1.07)       0.9 (0.36, 2.25)              0.53 (0.22, 1.28)     **0.23 (0.06, 0.89)**   0.81 (0.6, 1.09)        0.87 (0.35, 2.17)    0.56 (0.3, 1.04)        0.75 (0.51, 1.1)        1.01 (0.56, 1.81)       0.97 (0.66, 1.43)       1.21 (0.6, 2.45)        0.65 (0.36, 1.16)          0.89 (0.59, 1.33)        **Cis + Pac**           1.03 (0.63, 1.66)       1.63 (0.83, 3.2)     1.18 (0.56, 2.52)    1.44 (0.91, 2.28)       1.09 (0.62, 1.9)        1.53 (0.96, 2.42)       0.82 (0.4, 1.69)        2.63 (0.28, 24.89)     **1.64 (1.09, 2.48)**
                  **Cis + Topo- tecan**         0.84 (0.56, 1.27)       1.1 (0.44, 2.71)              0.65 (0.27, 1.54)     0.28 (0.07, 1.07)       0.99 (0.78, 1.26)       1.07 (0.44, 2.61)    0.68 (0.38, 1.24)       0.91 (0.64, 1.3)        1.23 (0.7, 2.16)        1.18 (0.83, 1.68)       1.48 (0.74, 2.94)       0.79 (0.46, 1.38)          1.09 (0.75, 1.57)        1.22 (0.83, 1.79)       **Cis + Topo- tecan**   1.59 (0.82, 3.07)    1.15 (0.55, 2.43)    1.4 (0.91, 2.17)        1.06 (0.62, 1.82)       1.49 (0.96, 2.31)       0.8 (0.4, 1.62)         2.57 (0.26, 25.55)     **1.6 (1.09, 2.36)**
                  **Cis + Vcr**                 1.36 (0.73, 2.54)       1.78 (0.66, 4.77)             1.05 (0.4, 2.72)      0.46 (0.11, 1.84)       1.6 (0.92, 2.8)         1.73 (0.62, 4.82)    1.11 (0.54, 2.27)       1.48 (0.85, 2.58)       1.99 (0.97, 4.08)       **1.91 (1.05, 3.48)**   2.39 (1.03, 5.56)       1.29 (0.65, 2.55)          1.76 (0.95, 3.28)        **1.98 (1.05, 3.71)**   1.62 (0.88, 2.97)       **Cis + Vcr**        0.73 (0.32, 1.67)    0.88 (0.49, 1.61)       0.67 (0.35, 1.28)       0.94 (0.51, 1.72)       0.51 (0.23, 1.12)       1.62 (0.15, 16.89)     1.01 (0.59, 1.72)
                  **Epi**                       1.05 (0.48, 2.26)       1.37 (0.46, 4.05)             0.8 (0.28, 2.32)      0.35 (0.08, 1.52)       1.23 (0.6, 2.53)        1.33 (0.43, 4.08)    0.85 (0.36, 1.99)       1.14 (0.55, 2.33)       1.53 (0.65, 3.58)       1.47 (0.69, 3.12)       1.84 (0.7, 4.79)        0.99 (0.43, 2.25)          1.35 (0.63, 2.93)        1.52 (0.7, 3.31)        1.24 (0.58, 2.66)       0.77 (0.33, 1.81)    **Epi**              1.21 (0.61, 2.42)       0.92 (0.44, 1.92)       1.29 (0.64, 2.58)       0.69 (0.29, 1.65)       2.22 (0.21, 23.8)      1.39 (0.74, 2.62)
                  **Flu**                       1 (0.63, 1.58)          1.3 (0.52, 3.25)              0.77 (0.32, 1.84)     0.33 (0.09, 1.28)       1.17 (0.83, 1.66)       1.27 (0.5, 3.19)     0.81 (0.44, 1.5)        1.08 (0.73, 1.61)       1.46 (0.8, 2.64)        1.4 (0.92, 2.13)        1.75 (0.85, 3.62)       0.94 (0.53, 1.67)          1.29 (0.83, 2.01)        1.45 (0.92, 2.28)       1.18 (0.77, 1.81)       0.73 (0.39, 1.37)    0.95 (0.44, 2.06)    **Flu**                 0.75 (0.47, 1.2)        1.06 (0.73, 1.54)       0.57 (0.3, 1.09)        1.83 (0.18, 18.13)     1.14 (0.87, 1.5)
                  **Flu + MitoC**               0.69 (0.37, 1.3)        0.9 (0.34, 2.44)              0.53 (0.2, 1.39)      0.23 (0.06, 0.94)       0.82 (0.47, 1.43)       0.88 (0.32, 2.46)    0.56 (0.27, 1.16)       0.75 (0.43, 1.32)       1.01 (0.49, 2.09)       0.97 (0.53, 1.78)       1.22 (0.52, 2.84)       0.66 (0.33, 1.3)           0.9 (0.48, 1.68)         1.01 (0.53, 1.9)        0.82 (0.45, 1.52)       0.51 (0.25, 1.06)    0.66 (0.28, 1.57)    0.7 (0.37, 1.31)        **Flu + MitoC**         1.41 (0.87, 2.26)       0.76 (0.38, 1.53)       2.42 (0.24, 24.57)     **1.52 (1.04, 2.21)**
                  **Hyd**                       0.99 (0.66, 1.5)        1.29 (0.53, 3.14)             0.76 (0.33, 1.78)     0.33 (0.09, 1.25)       1.17 (0.88, 1.54)       1.26 (0.51, 3.11)    0.81 (0.46, 1.42)       1.08 (0.81, 1.42)       1.45 (0.95, 2.21)       1.39 (0.97, 2.01)       1.74 (0.87, 3.49)       0.94 (0.56, 1.58)          1.28 (0.86, 1.9)         1.44 (0.96, 2.16)       1.18 (0.81, 1.71)       0.73 (0.41, 1.3)     0.95 (0.45, 1.98)    1 (0.65, 1.52)          1.43 (0.8, 2.56)        **Hyd**                 0.54 (0.28, 1.04)       1.72 (0.17, 17.1)      1.08 (0.81, 1.44)
                  **MitoC**                     0.77 (0.4, 1.49)        1 (0.36, 2.76)                0.59 (0.22, 1.57)     0.26 (0.06, 1.05)       0.9 (0.49, 1.65)        0.97 (0.34, 2.78)    0.62 (0.29, 1.32)       0.83 (0.46, 1.52)       1.12 (0.53, 2.38)       1.08 (0.57, 2.04)       1.35 (0.56, 3.22)       0.72 (0.35, 1.49)          0.99 (0.51, 1.92)        1.11 (0.57, 2.18)       0.91 (0.48, 1.74)       0.56 (0.26, 1.2)     0.73 (0.3, 1.78)     0.77 (0.4, 1.5)         1.11 (0.51, 2.38)       0.77 (0.41, 1.44)       **MitoC**               3.2 (0.3, 33.87)       **2 (1.11, 3.61)**
                  **Nedaplatin + Pac**          2.3 (0.16, 33.17)       2.99 (0.18, 48.73)            1.76 (0.11, 28.36)    0.77 (0.04, 14.79)      2.7 (0.19, 38.22)       2.92 (0.18, 47.27)   1.87 (0.12, 27.95)      2.49 (0.17, 35.72)      3.35 (0.23, 49.82)      3.22 (0.23, 46.2)       4.03 (0.26, 61.63)      2.17 (0.15, 32.15)         2.97 (0.21, 42.61)       3.33 (0.24, 46.43)      2.73 (0.19, 39.04)      1.68 (0.11, 25.26)   2.19 (0.14, 34.18)   2.3 (0.16, 33.36)       3.31 (0.22, 49.69)      2.31 (0.16, 33.24)      2.99 (0.2, 45.34)       **Nedaplatin + Pac**   0.62 (0.06, 6.14)
                  **Placebo**                   1.22 (0.86, 1.73)       1.59 (0.68, 3.69)             0.93 (0.42, 2.09)     0.41 (0.11, 1.49)       **1.43 (1.15, 1.78)**   1.55 (0.64, 3.75)    0.99 (0.6, 1.63)        **1.32 (1.07, 1.64)**   **1.78 (1.08, 2.93)**   **1.71 (1.26, 2.33)**   **2.14 (1.1, 4.17)**    1.15 (0.73, 1.8)           **1.57 (1.11, 2.23)**    **1.77 (1.23, 2.54)**   **1.45 (1.04, 2)**      0.89 (0.53, 1.49)    1.16 (0.58, 2.31)    1.22 (0.86, 1.75)       **1.75 (1.04, 2.95)**   1.23 (0.94, 1.6)        1.59 (0.9, 2.78)        0.53 (0.04, 7.57)      **Placebo**

###### Mixed evidence of 5-year overall survival and recurrence-free survival for different treatments

  5-year RFS                                                                                                                                                                                                                                                                                                                                                                                                                                
  ----------------------------- --------------------- ----------------------------- --------------------- ----------------------- ---------------------- ----------------------- ------------------- ----------------------- ----------------------- -------------------------- ------------------- ------------------- ------------------- ----------------------- ----------------------- ----------------------- ----------------------- --
  **5-year OS**                 **Ble + Cis + Ifo**   **Ble + Cis + Ifo**                                                                                                                                                                                                                                                                                                                                                                   
  **Ble + Cis + MitoC + Vbl**   0.72 (0.28, 1.85)     **Ble + Cis + MitoC + Vbl**                                                                                                                                                                                                                                                                                                                                                           
  **Ble + Cis + Vbl**           1.3 (0.53, 3.2)       1.79 (0.59, 5.42)             **Ble + Cis + Vbl**   1.05 (0.5, 2.22)        0.92 (0.49, 1.72)      0.59 (0.26, 1.32)       1.48 (0.69, 3.16)   0.81 (0.43, 1.51)       0.66 (0.3, 1.44)        0.95 (0.46, 1.95)          1.14 (0.52, 2.47)   1.02 (0.32, 3.23)   1.04 (0.55, 1.98)   0.82 (0.41, 1.65)       1.04 (0.54, 2.01)       0.47 (0.21, 1.07)       1.18 (0.66, 2.12)       
  **Ble + Cis + Vcr**           3.03 (0.99, 9.32)     **4.19 (1.15, 15.24)**        2.34 (0.66, 8.29)     **Ble + Cis + Vcr**     0.87 (0.52, 1.48)      0.56 (0.27, 1.16)       1.41 (0.72, 2.76)   0.77 (0.46, 1.29)       0.62 (0.31, 1.26)       0.9 (0.48, 1.69)           1.08 (0.54, 2.16)   0.97 (0.32, 2.91)   0.99 (0.57, 1.7)    0.78 (0.42, 1.43)       0.99 (0.56, 1.73)       **0.45 (0.21, 0.94)**   1.12 (0.71, 1.79)       
  **Cis**                       0.8 (0.47, 1.36)      1.1 (0.48, 2.53)              0.62 (0.28, 1.36)     **0.26 (0.09, 0.74)**   **Cis**                0.64 (0.39, 1.06)       1.61 (0.94, 2.76)   0.88 (0.65, 1.19)       0.71 (0.41, 1.24)       1.03 (0.63, 1.68)          1.24 (0.7, 2.18)    1.11 (0.4, 3.09)    1.13 (0.83, 1.53)   0.89 (0.56, 1.4)        1.13 (0.8, 1.6)         **0.51 (0.28, 0.96)**   **1.29 (1.01, 1.63)**   
  **Cis + Doc**                 0.52 (0.25, 1.09)     0.72 (0.27, 1.9)              0.4 (0.16, 1.03)      **0.17 (0.05, 0.54)**   0.65 (0.39, 1.08)      **Cis + Doc**           2.51 (1.2, 5.24)    1.37 (0.77, 2.46)       1.11 (0.53, 2.35)       1.61 (0.8, 3.23)           1.93 (0.9, 4.1)     1.73 (0.55, 5.41)   1.76 (0.98, 3.16)   1.38 (0.7, 2.73)        1.76 (0.96, 3.24)       0.8 (0.36, 1.78)        **2.01 (1.15, 3.49)**   
  **Cis + Epi**                 1.18 (0.6, 2.33)      1.63 (0.64, 4.15)             0.91 (0.37, 2.24)     0.39 (0.13, 1.19)       1.48 (0.88, 2.51)      **2.28 (1.1, 4.75)**    **Cis + Epi**       **0.55 (0.32, 0.94)**   **0.44 (0.22, 0.91)**   0.64 (0.33, 1.22)          0.77 (0.38, 1.56)   0.69 (0.23, 2.09)   0.7 (0.4, 1.23)     0.55 (0.3, 1.03)        0.7 (0.39, 1.25)        **0.32 (0.15, 0.68)**   0.8 (0.49, 1.3)         
  **Cis + Flu**                 0.89 (0.53, 1.5)      1.23 (0.54, 2.81)             0.69 (0.31, 1.51)     **0.29 (0.1, 0.82)**    1.11 (0.85, 1.46)      1.71 (0.96, 3.06)       0.75 (0.45, 1.26)   **Cis + Flu**           0.81 (0.47, 1.39)       1.17 (0.72, 1.89)          1.4 (0.8, 2.46)     1.26 (0.45, 3.5)    1.28 (0.91, 1.81)   1.01 (0.64, 1.58)       1.28 (0.93, 1.77)       0.58 (0.32, 1.08)       **1.46 (1.17, 1.83)**   
  **Cis + Flu + Hyd**           0.64 (0.33, 1.23)     0.88 (0.35, 2.21)             0.49 (0.2, 1.19)      **0.21 (0.07, 0.64)**   0.79 (0.5, 1.27)       1.22 (0.61, 2.45)       0.54 (0.28, 1.04)   0.71 (0.45, 1.13)       **Cis + Flu + Hyd**     1.44 (0.73, 2.86)          1.73 (0.83, 3.64)   1.55 (0.5, 4.82)    1.58 (0.88, 2.86)   1.25 (0.64, 2.41)       **1.59 (1.03, 2.45)**   0.72 (0.33, 1.58)       **1.81 (1.06, 3.08)**   
  **Cis + Metho- trexate**      0.95 (0.51, 1.78)     1.32 (0.54, 3.22)             0.73 (0.31, 1.73)     **0.31 (0.11, 0.93)**   1.19 (0.76, 1.88)      1.84 (0.93, 3.64)       0.81 (0.43, 1.49)   1.07 (0.69, 1.67)       1.5 (0.82, 2.74)        **Cis + Metho- trexate**   1.2 (0.61, 2.34)    1.07 (0.36, 3.19)   1.1 (0.66, 1.82)    0.86 (0.48, 1.54)       1.1 (0.65, 1.86)        0.5 (0.24, 1.02)        1.25 (0.82, 1.92)       
  **Cis + Vcr**                 1.26 (0.65, 2.48)     1.75 (0.69, 4.42)             0.97 (0.4, 2.38)      0.42 (0.14, 1.27)       1.58 (0.94, 2.66)      **2.44 (1.18, 5.05)**   1.07 (0.55, 2.08)   1.42 (0.85, 2.37)       **1.99 (1.04, 3.83)**   1.33 (0.72, 2.44)          **Cis + Vcr**       0.9 (0.29, 2.76)    0.91 (0.51, 1.64)   0.72 (0.38, 1.37)       0.92 (0.5, 1.67)        **0.42 (0.19, 0.9)**    1.04 (0.62, 1.74)       
  **Epi**                       0.92 (0.43, 1.96)     1.27 (0.47, 3.42)             0.71 (0.27, 1.85)     **0.3 (0.09, 0.97)**    1.15 (0.62, 2.14)      1.77 (0.79, 3.97)       0.78 (0.37, 1.65)   1.03 (0.56, 1.91)       1.45 (0.69, 3.03)       0.96 (0.48, 1.95)          0.73 (0.34, 1.53)   **Epi**             1.02 (0.36, 2.88)   0.8 (0.27, 2.35)        1.02 (0.36, 2.91)       0.47 (0.15, 1.47)       1.16 (0.43, 3.16)       
  **Flu**                       0.95 (0.52, 1.71)     1.31 (0.55, 3.12)             0.73 (0.32, 1.68)     **0.31 (0.11, 0.91)**   1.18 (0.85, 1.64)      1.82 (0.99, 3.35)       0.8 (0.44, 1.44)    1.06 (0.72, 1.56)       1.49 (0.86, 2.58)       0.99 (0.59, 1.67)          0.75 (0.42, 1.34)   1.03 (0.52, 2.02)   **Flu**             0.79 (0.49, 1.27)       1 (0.67, 1.5)           **0.46 (0.24, 0.86)**   1.14 (0.86, 1.5)        
  **Flu + MitoC**               0.69 (0.35, 1.37)     0.95 (0.37, 2.43)             0.53 (0.22, 1.31)     **0.23 (0.07, 0.7)**    0.86 (0.51, 1.47)      1.33 (0.63, 2.79)       0.58 (0.29, 1.15)   0.78 (0.46, 1.31)       1.09 (0.56, 2.12)       0.72 (0.39, 1.35)          0.55 (0.28, 1.07)   0.75 (0.35, 1.6)    0.73 (0.4, 1.32)    **Flu + MitoC**         1.27 (0.77, 2.1)        0.58 (0.29, 1.16)       1.45 (0.98, 2.14)       
  **Hyd**                       0.98 (0.57, 1.69)     1.35 (0.58, 3.13)             0.75 (0.34, 1.68)     **0.32 (0.11, 0.91)**   1.22 (0.93, 1.6)       **1.88 (1.06, 3.36)**   0.83 (0.48, 1.42)   1.1 (0.84, 1.43)        **1.54 (1.05, 2.25)**   1.02 (0.64, 1.64)          0.77 (0.45, 1.32)   1.06 (0.56, 2)      1.03 (0.69, 1.53)   1.42 (0.82, 2.45)       **Hyd**                 **0.46 (0.24, 0.87)**   1.14 (0.83, 1.55)       
  **MitoC**                     0.74 (0.34, 1.59)     1.02 (0.37, 2.77)             0.57 (0.21, 1.5)      **0.24 (0.07, 0.79)**   0.92 (0.48, 1.75)      1.42 (0.62, 3.22)       0.62 (0.29, 1.34)   0.83 (0.44, 1.56)       1.16 (0.54, 2.47)       0.77 (0.38, 1.58)          0.58 (0.27, 1.25)   0.8 (0.35, 1.85)    0.78 (0.39, 1.55)   1.07 (0.49, 2.32)       0.75 (0.39, 1.45)       **MitoC**               **2.5 (1.41, 4.43)**    
  **Placebo**                   1.15 (0.71, 1.86)     1.59 (0.71, 3.54)             0.88 (0.41, 1.89)     0.38 (0.14, 1.04)       **1.44 (1.15, 1.8)**   **2.22 (1.27, 3.87)**   0.97 (0.6, 1.56)    **1.29 (1.05, 1.59)**   **1.81 (1.15, 2.86)**   1.2 (0.81, 1.79)           0.91 (0.57, 1.45)   1.25 (0.7, 2.24)    1.21 (0.86, 1.71)   **1.67 (1.02, 2.71)**   1.18 (0.91, 1.52)       1.56 (0.85, 2.86)       **Placebo**             

###### *P*-score for each treatment under the outcomes of overall survival and recurrence-free survival

  Regimen                       Overall survival   Recurrence-free survival                                       
  ----------------------------- ------------------ -------------------------- ----------- ----------- ----------- -----------
  **Ble + Cis + Ifo**           0.438              0.405                      0.429       0.648       **0.832**   \-
  **Ble + Cis + MitoC + Vbl**   **0.692**          0.638                      0.686       \-          \-          \-
  **Ble + Cis + Vbl**           0.529              0.274                      0.259       0.556       0.428       0.429
  **Ble + Cis + Vcr**           0.348              0.070                      0.024       0.307       0.374       0.373
  **Cis**                       0.559              0.584                      0.680       0.594       0.471       0.524
  **Cis + Doc**                 0.453              0.618                      **0.918**   0.359       0.576       **0.857**
  **Cis + Epi**                 0.573              0.261                      0.277       0.200       0.119       0.101
  **Cis + Flu**                 0.493              0.494                      0.555       **0.716**   0.598       0.674
  **Cis + Flu + Hyd**           **0.670**          0.768                      **0.834**   0.623       0.688       **0.801**
  **Cis + Ifo**                 0.619              **0.771**                  \-          **0.690**   **0.810**   \-
  **Cis + Ifo + Pac**           0.582              **0.856**                  \-          0.612       0.799       \-
  **Cis + Methotrexate**        0.442              0.373                      0.474       0.417       0.422       0.483
  **Cis + Mitolactol**          0.438              0.685                      \-          0.466       0.118       \-
  **Cis + Pac**                 0.389              **0.791**                  \-          0.550       0.706       \-
  **Cis + Topotecan**           0.423              0.593                      \-          0.483       0.686       \-
  **Cis + Vcr**                 0.484              0.198                      0.225       0.304       0.270       0.303
  **Epi**                       0.531              0.406                      0.511       0.577       0.541       0.430
  **Flu**                       0.305              0.414                      0.477       0.369       0.348       0.373
  **Flu + MitoC**               0.463              0.750                      **0.767**   0.495       0.632       0.641
  **Hyd**                       **0.668**          0.409                      0.436       0.583       0.288       0.367
  **MitoC**                     0.563              0.664                      0.700       **0.653**   **0.820**   **0.940**
  **Nedaplatin + Pac**          \-                 0.264                      \-          \-          0.264       \-
  **Placebo**                   0.338              0.214                      0.248       0.296       0.212       0.203

Recurrence-free survival (RFS) {#s2_3}
------------------------------

As to 3-year and 5-year RFS, another primary outcomes, were evaluated in 21 and 14 trials respectively. According to Tables [2](#T2){ref-type="table"}--[4](#T4){ref-type="table"}, nine of them were noticeably better than treatments without chemotherapy for 3-year RFS, as mitomycin C (HR = 2, 95% CI: 1.11-3.61), cisplatin+ifosfamide+paclitaxel (HR = 1.94, 95% CrI: 1.03-3.68), bleomycin+cisplatin+ifosfamide (HR = 1.91, 95% CrI: 1.31-2.8), cisplatin+ifosfamide (HR = 1.85, 95% CrI: 1.33-2.56), cisplatin+paclitaxel (HR = 1.64, 95% CrI: 1.03-3.68), cisplatin+topotecan (HR = 1.6, 95% CrI: 1.09-2.36), fluorouracil+mitomycin C (HR = 1.52, 95% CrI: 1.04-2.21), cisplatin+fluorouracil (HR = 1.45, 95% CrI: 1.18-1.79), cisplatin (HR = 1.3, 95% CrI: 1.05-1.6). Besides, mitomycin C (HR = 2.5, 95% CI: 1.41-4.43), cisplatin+docetaxel (HR = -2.01, 95% CrI: 1.15-3.49), cisplatin+fluorouracil+hydroxyurea (HR = 1.81, 95% CrI: 1.06-3.08), cisplatin+fluorouracil (HR = 1.46, 95% CrI: 1.17-1.83), cisplatin (HR = 1.29, 95% CrI: 1.01-1.63) possessed obvious strength in 5 year RFS. In Table [5](#T5){ref-type="table"}, ranking analysis showed that mitomycin C had excellent performance in both short term and long term RFS. Cisplatin+ifosfamide was also efficacious in 1-year and 3-year RFS and since the lack of 5-year RFS, we could not estimate its long term efficacy. Cisplatin+docetaxel and cisplatin+ fluorouracil+hydroxyurea had advantage in improving 5-year RFS, which verified their outstanding efficacy in long-term RFS.

Recurrence {#s2_4}
----------

In terms of the secondary outcome of recurrence, 19 chemotherapy strategies were compared with placebo in Table [6](#T6){ref-type="table"}. Cisplatin+ifosfamide+paclitaxel (OR = 0.15, 95% CrI: 0.03-0.77), cisplatin+ ifosfamide (OR = 0.17, 95% CrI: 0.05-0.53), cisplatin+fluorouracil (OR = 0.45, 95% CrI: 0.29-0.71), fluorouracil (OR = 0.51, 95% CrI: 0.26-0.96), and cisplatin (OR = 0.59, 95% CrI: 0.37-0.93) were outstanding among them. Based on their SUCRA illustrated in Figure [2](#F2){ref-type="fig"} and Table [8](#T8){ref-type="table"}, cisplatin+ifosfamide (0.93) was the optimal combination, cisplatin+ifosfamide+paclitaxel (0.91) was the second, and the third one was cisplatin+docetaxel (0.74).

![Cumulative ranking probability curves for recurrence and distant metastasis\
**(A)** recurrence; **(B)** distant metastasis.](oncotarget-08-49515-g002){#F2}

###### Mixed evidence of recurrence for different treatments

                          Ble+Cis+Ifo              Ble+Cis+MitoC+Vbl        Ble+Cis+Vbl              Ble+Cis+Vcr              Cis                      Cis+Doc              Cis+Epi                  Cis+Flu                 Cis+Ifo                 Cis+Ifo+Pac             Cis+Methotrexate       Cis+Mitolactol       Cis+Topotecan        Cis+Vcr              Epi                  Flu                     Cis+Flu+Hyd          Flu+MitoC            Hyd                  Placebo
  ----------------------- ------------------------ ------------------------ ------------------------ ------------------------ ------------------------ -------------------- ------------------------ ----------------------- ----------------------- ----------------------- ---------------------- -------------------- -------------------- -------------------- -------------------- ----------------------- -------------------- -------------------- -------------------- --------------------
  **Ble+Cis+Ifo**         **Ble+Cis+Ifo**          1.73 (0.33, 8.40)        1.68 (0.48, 5.90)        1.77 (0.53, 5.58)        0.85 (0.33, 2.06)        0.51 (0.11, 2.12)    1.72 (0.44, 6.58)        0.65 (0.25, 1.59)       0.24 (0.07, 0.74)       0.22 (0.04, 1.09)       1.18 (0.23, 5.85)      0.91 (0.17, 5.27)    0.61 (0.13, 2.89)    1.50 (0.37, 5.48)    0.77 (0.18, 2.93)    0.73 (0.25, 2.00)       0.62 (0.16, 2.13)    0.56 (0.15, 1.92)    1.02 (0.33, 2.68)    1.43 (0.61, 3.20)
  **Ble+Cis+MitoC+Vbl**   0.58 (0.12, 2.99)        **Ble+Cis+MitoC+Vbl**    0.98 (0.19, 5.19)        1.04 (0.21, 5.24)        0.49 (0.11, 2.13)        0.30 (0.05, 1.81)    1.01 (0.17, 5.95)        0.38 (0.09, 1.61)       0.14 (0.02, 0.86)       0.13 (0.02, 1.08)       0.69 (0.10, 4.76)      0.53 (0.07, 5.08)    0.36 (0.05, 2.47)    0.87 (0.16, 4.95)    0.44 (0.08, 2.62)    0.42 (0.09, 1.93)       0.36 (0.07, 1.90)    0.33 (0.06, 1.74)    0.59 (0.13, 2.53)    0.84 (0.21, 3.32)
  **Ble+Cis+Vbl**         0.60 (0.17, 2.10)        1.02 (0.19, 5.34)        **Ble+Cis+Vbl**          1.06 (0.29, 3.76)        0.50 (0.17, 1.46)        0.30 (0.06, 1.42)    1.02 (0.25, 4.33)        0.38 (0.13, 1.10)       0.14 (0.03, 0.65)       0.13 (0.02, 0.87)       0.70 (0.13, 3.75)      0.54 (0.09, 3.82)    0.37 (0.07, 1.85)    0.89 (0.20, 3.71)    0.46 (0.10, 1.99)    0.43 (0.13, 1.36)       0.37 (0.09, 1.44)    0.33 (0.08, 1.28)    0.60 (0.19, 1.78)    0.85 (0.33, 2.19)
  **Ble+Cis+Vcr**         0.56 (0.18, 1.88)        0.97 (0.19, 4.83)        0.95 (0.27, 3.39)        **Ble+Cis+Vcr**          0.48 (0.18, 1.25)        0.29 (0.06, 1.27)    0.97 (0.25, 3.76)        0.37 (0.14, 0.94)       0.14 (0.03, 0.57)       0.12 (0.02, 0.78)       0.67 (0.13, 3.31)      0.51 (0.09, 3.56)    0.34 (0.07, 1.69)    0.84 (0.21, 3.27)    0.43 (0.10, 1.70)    0.41 (0.14, 1.17)       0.35 (0.09, 1.27)    0.31 (0.09, 1.12)    0.57 (0.19, 1.53)    0.81 (0.35, 1.87)
  **Cis**                 1.18 (0.48, 3.05)        2.03 (0.47, 8.74)        1.99 (0.68, 5.73)        2.10 (0.80, 5.45)        **Cis**                  0.60 (0.19, 1.86)    2.05 (0.64, 6.67)        0.76 (0.44, 1.31)       0.29 (0.09, 0.89)       0.26 (0.05, 1.31)       1.40 (0.32, 6.03)      1.07 (0.23, 6.03)    0.73 (0.21, 2.59)    1.77 (0.55, 5.67)    0.91 (0.27, 3.02)    0.85 (0.42, 1.71)       0.74 (0.27, 1.84)    0.66 (0.23, 1.89)    1.21 (0.59, 2.18)    1.69 (1.06, 2.68)
  **Cis+Doc**             1.97 (0.47, 8.71)        3.38 (0.55, 21.43)       3.35 (0.71, 16.05)       3.51 (0.79, 15.93)       1.68 (0.54, 5.27)        **Cis+Doc**          3.39 (0.66, 18.11)       1.28 (0.36, 4.55)       0.48 (0.10, 2.47)       0.44 (0.06, 3.23)       2.34 (0.37, 14.68)     1.81 (0.26, 14.25)   1.22 (0.22, 6.64)    2.97 (0.57, 15.12)   1.52 (0.29, 8.02)    1.44 (0.37, 5.51)       1.23 (0.26, 5.29)    1.12 (0.23, 5.28)    2.01 (0.50, 7.15)    2.84 (0.82, 9.70)
  **Cis+Epi**             0.58 (0.15, 2.27)        0.99 (0.17, 5.72)        0.98 (0.23, 4.08)        1.03 (0.27, 4.03)        0.49 (0.15, 1.55)        0.29 (0.06, 1.51)    **Cis+Epi**              0.38 (0.11, 1.19)       0.14 (0.03, 0.68)       0.13 (0.02, 0.91)       0.68 (0.12, 3.88)      0.53 (0.08, 3.96)    0.36 (0.06, 1.93)    0.87 (0.19, 3.85)    0.45 (0.09, 2.03)    0.42 (0.11, 1.45)       0.36 (0.08, 1.52)    0.33 (0.07, 1.36)    0.59 (0.16, 1.89)    0.83 (0.28, 2.38)
  **Cis+Flu**             1.54 (0.63, 4.03)        2.65 (0.62, 11.16)       2.61 (0.91, 7.46)        **2.73 (1.07, 7.22)**    1.31 (0.76, 2.26)        0.78 (0.22, 2.77)    2.66 (0.84, 8.77)        **Cis+Flu**             0.38 (0.11, 1.24)       0.34 (0.07, 1.83)       1.83 (0.42, 7.83)      1.41 (0.28, 8.31)    0.95 (0.24, 3.65)    2.30 (0.72, 7.41)    1.18 (0.36, 3.93)    1.11 (0.51, 2.43)       0.96 (0.33, 2.58)    0.86 (0.29, 2.49)    1.57 (0.77, 2.83)    2.21 (1.40, 3.53)
  **Cis+Ifo**             **4.08 (1.35, 13.49)**   **7.12 (1.17, 42.43)**   **6.91 (1.55, 31.52)**   **7.30 (1.74, 30.66)**   **3.47 (1.13, 11.09)**   2.06 (0.41, 10.46)   **7.10 (1.48, 35.27)**   2.65 (0.81, 9.06)       **Cis+Ifo**             0.90 (0.30, 2.89)       4.87 (0.78, 30.22)     3.71 (0.92, 18.13)   2.51 (0.46, 13.93)   6.09 (1.28, 29.86)   3.15 (0.62, 15.87)   2.96 (0.81, 11.07)      2.53 (0.57, 10.86)   2.29 (0.51, 10.21)   4.14 (1.12, 14.63)   5.86 (1.90, 19.01)
  **Cis+Ifo+Pac**         4.53 (0.92, 22.95)       7.72 (0.93, 64.19)       **7.58 (1.15, 48.69)**   **8.00 (1.27, 47.80)**   3.81 (0.76, 18.89)       2.28 (0.31, 16.11)   **7.78 (1.09, 54.27)**   2.92 (0.55, 14.99)      1.11 (0.35, 3.31)       **Cis+Ifo+Pac**         5.36 (0.61, 44.30)     4.10 (0.69, 27.85)   2.75 (0.35, 20.72)   6.67 (0.94, 47.95)   3.43 (0.48, 25.04)   3.25 (0.58, 18.35)      2.79 (0.43, 16.82)   2.52 (0.39, 16.28)   4.61 (0.79, 23.56)   6.47 (1.28, 31.85)
  **Cis+Methotrexate**    0.85 (0.17, 4.28)        1.45 (0.21, 10.09)       1.42 (0.27, 7.68)        1.49 (0.30, 7.58)        0.72 (0.17, 3.11)        0.43 (0.07, 2.67)    1.46 (0.26, 8.52)        0.55 (0.13, 2.36)       0.21 (0.03, 1.28)       0.19 (0.02, 1.63)       **Cis+Methotrexate**   0.78 (0.10, 6.92)    0.51 (0.08, 3.57)    1.26 (0.22, 7.11)    0.65 (0.11, 3.91)    0.61 (0.13, 2.83)       0.52 (0.09, 2.79)    0.47 (0.09, 2.50)    0.86 (0.19, 3.69)    1.21 (0.31, 4.82)
  **Cis+Mitolactol**      1.09 (0.19, 5.90)        1.90 (0.20, 15.11)       1.85 (0.26, 11.69)       1.97 (0.28, 11.13)       0.93 (0.17, 4.32)        0.55 (0.07, 3.78)    1.89 (0.25, 12.86)       0.71 (0.12, 3.55)       0.27 (0.06, 1.09)       0.24 (0.04, 1.46)       1.29 (0.14, 10.22)     **Cis+Mitolactol**   0.67 (0.08, 4.90)    1.64 (0.21, 10.64)   0.84 (0.10, 5.77)    0.79 (0.12, 4.18)       0.68 (0.09, 4.06)    0.62 (0.08, 3.85)    1.11 (0.17, 5.60)    1.58 (0.27, 7.52)
  **Cis+Topotecan**       1.63 (0.35, 7.93)        2.79 (0.41, 19.03)       2.74 (0.54, 14.35)       2.90 (0.59, 14.27)       1.37 (0.39, 4.81)        0.82 (0.15, 4.47)    2.80 (0.52, 15.94)       1.05 (0.27, 4.13)       0.40 (0.07, 2.18)       0.36 (0.05, 2.88)       1.94 (0.28, 12.66)     1.50 (0.20, 12.39)   **Cis+Topotecan**    2.41 (0.43, 13.44)   1.25 (0.22, 6.98)    1.18 (0.28, 4.94)       1.01 (0.20, 4.66)    0.90 (0.18, 4.57)    1.65 (0.39, 6.37)    2.33 (0.61, 8.94)
  **Cis+Vcr**             0.67 (0.18, 2.70)        1.16 (0.20, 6.39)        1.12 (0.27, 4.91)        1.19 (0.31, 4.66)        0.57 (0.18, 1.82)        0.34 (0.07, 1.75)    1.15 (0.26, 5.20)        0.43 (0.13, 1.39)       0.16 (0.03, 0.78)       0.15 (0.02, 1.06)       0.79 (0.14, 4.46)      0.61 (0.09, 4.77)    0.41 (0.07, 2.32)    **Cis+Vcr**          0.52 (0.11, 2.40)    0.49 (0.14, 1.68)       0.42 (0.09, 1.74)    0.38 (0.09, 1.62)    0.68 (0.19, 2.18)    0.96 (0.33, 2.83)
  **Epi**                 1.30 (0.34, 5.48)        2.25 (0.38, 13.27)       2.19 (0.50, 9.60)        2.30 (0.59, 9.59)        1.10 (0.33, 3.66)        0.66 (0.12, 3.45)    2.24 (0.49, 10.59)       0.85 (0.25, 2.78)       0.32 (0.06, 1.60)       0.29 (0.04, 2.07)       1.54 (0.26, 9.12)      1.19 (0.17, 9.58)    0.80 (0.14, 4.63)    1.93 (0.42, 9.12)    **Epi**              0.94 (0.26, 3.39)       0.81 (0.18, 3.45)    0.72 (0.16, 3.21)    1.32 (0.36, 4.47)    1.87 (0.62, 5.71)
  **Flu**                 1.37 (0.50, 4.04)        2.38 (0.52, 11.00)       2.34 (0.73, 7.50)        2.46 (0.85, 7.23)        1.17 (0.59, 2.38)        0.69 (0.18, 2.71)    2.38 (0.69, 8.71)        0.90 (0.41, 1.96)       0.34 (0.09, 1.24)       0.31 (0.05, 1.73)       1.64 (0.35, 7.77)      1.26 (0.24, 8.06)    0.85 (0.20, 3.58)    2.06 (0.59, 7.20)    1.06 (0.30, 3.92)    **Flu**                 0.86 (0.26, 2.69)    0.77 (0.29, 2.11)    1.41 (0.56, 3.16)    1.98 (1.03, 3.91)
  **Cis+Flu+Hyd**         1.61 (0.47, 6.28)        2.79 (0.53, 15.34)       2.72 (0.69, 11.11)       2.85 (0.79, 11.08)       1.36 (0.54, 3.74)        0.81 (0.19, 3.82)    2.79 (0.66, 12.37)       1.04 (0.39, 3.05)       0.39 (0.09, 1.76)       0.36 (0.06, 2.34)       1.91 (0.36, 10.73)     1.47 (0.25, 10.55)   0.99 (0.21, 5.00)    2.39 (0.57, 10.76)   1.24 (0.29, 5.68)    1.16 (0.37, 3.81)       **Cis+Flu+Hyd**      0.90 (0.24, 3.75)    1.64 (0.61, 4.13)    2.30 (0.88, 6.50)
  **Flu+MitoC**           1.78 (0.52, 6.68)        3.07 (0.57, 16.69)       3.02 (0.78, 11.79)       3.18 (0.90, 11.66)       1.51 (0.53, 4.27)        0.90 (0.19, 4.32)    3.06 (0.74, 13.35)       1.16 (0.40, 3.43)       0.44 (0.10, 1.95)       0.40 (0.06, 2.58)       2.11 (0.40, 11.57)     1.62 (0.26, 11.85)   1.11 (0.22, 5.51)    2.66 (0.62, 11.38)   1.38 (0.31, 6.10)    1.29 (0.47, 3.44)       1.11 (0.27, 4.24)    **Flu+MitoC**        1.82 (0.56, 5.36)    2.56 (0.95, 6.80)
  **Hyd**                 0.98 (0.37, 3.02)        1.69 (0.40, 7.94)        1.67 (0.56, 5.31)        1.75 (0.66, 5.30)        0.83 (0.46, 1.70)        0.50 (0.14, 2.00)    1.69 (0.53, 6.32)        0.64 (0.35, 1.29)       **0.24 (0.07, 0.89)**   0.22 (0.04, 1.27)       1.16 (0.27, 5.40)      0.90 (0.18, 5.81)    0.61 (0.16, 2.58)    1.46 (0.46, 5.29)    0.76 (0.22, 2.80)    0.71 (0.32, 1.79)       0.61 (0.24, 1.63)    0.55 (0.19, 1.79)    **Hyd**              1.41 (0.81, 2.73)
  **Placebo**             0.70 (0.31, 1.64)        1.19 (0.30, 4.73)        1.18 (0.46, 3.05)        1.24 (0.54, 2.85)        **0.59 (0.37, 0.94)**    0.35 (0.10, 1.23)    1.20 (0.42, 3.60)        **0.45 (0.28, 0.71)**   **0.17 (0.05, 0.53)**   **0.15 (0.03, 0.78)**   0.83 (0.21, 3.27)      0.63 (0.13, 3.66)    0.43 (0.11, 1.64)    1.04 (0.35, 3.03)    0.54 (0.18, 1.61)    **0.51 (0.26, 0.97)**   0.43 (0.15, 1.13)    0.39 (0.15, 1.05)    0.71 (0.37, 1.24)    **Placebo**

###### Mixed evidence of distant metastasis for different treatments

                           Ble+Cis+Ifo         Ble+Cis+MitoC+Vbl        Ble+Cis+Vbl          Ble+Cis+Vcr          Cis                  Cis+Doc              Cis+Epi              Cis+Flu              Cis+Metho-trexate        Cis+Pac              Cis+Vcr              Epi                     Flu                  Flu+MitoC            Hyd                  Placebo
  ------------------------ ------------------- ------------------------ -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- ------------------------ -------------------- -------------------- ----------------------- -------------------- -------------------- -------------------- --------------------
  **Ble+Cis+Ifo**          **Ble+Cis+Ifo**     5.29 (0.65, 51.92)       2.19 (0.38, 14.21)   2.22 (0.34, 16.32)   2.75 (0.59, 15.69)   1.42 (0.15, 14.00)   2.43 (0.40, 17.76)   2.50 (0.55, 14.39)   4.02 (0.66, 28.87)       4.04 (0.65, 29.51)   2.68 (0.45, 18.96)   0.92 (0.14, 6.74)       2.03 (0.40, 12.01)   2.02 (0.36, 12.74)   2.69 (0.43, 22.55)   3.29 (0.79, 16.69)
  **Ble+Cis +MitoC+Vbl**   0.19 (0.02, 1.53)   **Ble+Cis +MitoC+Vbl**   0.41 (0.06, 2.64)    0.42 (0.05, 2.88)    0.52 (0.09, 2.70)    0.26 (0.02, 2.58)    0.46 (0.06, 3.16)    0.47 (0.09, 2.57)    0.77 (0.10, 5.07)        0.76 (0.10, 5.47)    0.50 (0.07, 3.30)    0.18 (0.02, 1.28)       0.38 (0.06, 2.14)    0.38 (0.06, 2.39)    0.50 (0.07, 3.95)    0.63 (0.12, 3.03)
  **Ble+Cis+Vbl**          0.46 (0.07, 2.65)   2.46 (0.38, 17.09)       **Ble+Cis+Vbl**      1.02 (0.21, 5.11)    1.29 (0.37, 4.25)    0.67 (0.09, 4.65)    1.15 (0.25, 5.13)    1.17 (0.36, 4.06)    1.92 (0.40, 8.31)        1.90 (0.38, 8.67)    1.25 (0.27, 5.50)    0.44 (0.08, 2.07)       0.95 (0.25, 3.35)    0.94 (0.22, 3.78)    1.24 (0.25, 7.02)    1.54 (0.53, 4.32)
  **Ble+Cis+Vcr**          0.45 (0.06, 2.97)   2.38 (0.35, 18.82)       0.98 (0.20, 4.79)    **Ble+Cis+Vcr**      1.24 (0.32, 4.73)    0.65 (0.08, 4.98)    1.10 (0.21, 5.91)    1.12 (0.31, 4.80)    1.87 (0.36, 9.48)        1.81 (0.33, 9.93)    1.21 (0.23, 6.07)    0.42 (0.08, 2.27)       0.92 (0.21, 3.68)    0.92 (0.19, 4.26)    1.21 (0.23, 7.69)    1.50 (0.45, 4.99)
  **Cis**                  0.36 (0.06, 1.68)   1.92 (0.37, 11.15)       0.77 (0.24, 2.70)    0.80 (0.21, 3.10)    **Cis**              0.51 (0.10, 2.46)    0.89 (0.25, 3.24)    0.90 (0.48, 1.92)    1.48 (0.42, 5.18)        1.48 (0.52, 4.15)    0.98 (0.27, 3.29)    0.34 (0.09, 1.27)       0.74 (0.33, 1.57)    0.74 (0.25, 2.11)    0.96 (0.28, 3.88)    1.20 (0.65, 2.16)
  **Cis+Doc**              0.70 (0.07, 6.59)   3.81 (0.39, 40.21)       1.48 (0.22, 11.65)   1.53 (0.20, 12.84)   1.95 (0.41, 10.07)   **Cis+Doc**          1.72 (0.23, 13.70)   1.75 (0.34, 11.17)   2.84 (0.38, 23.43)       2.82 (0.44, 19.85)   1.90 (0.25, 14.22)   0.66 (0.08, 5.24)       1.43 (0.24, 8.61)    1.42 (0.21, 9.99)    1.88 (0.27, 16.27)   2.33 (0.43, 13.23)
  **Cis+Epi**              0.41 (0.06, 2.53)   2.19 (0.32, 16.23)       0.87 (0.20, 4.08)    0.91 (0.17, 4.67)    1.13 (0.31, 4.02)    0.58 (0.07, 4.32)    **Cis+Epi**          1.02 (0.30, 3.89)    1.66 (0.33, 8.04)        1.66 (0.31, 8.47)    1.09 (0.22, 5.01)    0.39 (0.07, 1.95)       0.83 (0.20, 3.24)    0.83 (0.18, 3.53)    1.09 (0.22, 6.59)    1.35 (0.43, 4.14)
  **Cis+Flu**              0.40 (0.07, 1.80)   2.13 (0.39, 11.76)       0.86 (0.25, 2.75)    0.89 (0.21, 3.21)    1.11 (0.52, 2.08)    0.57 (0.09, 2.97)    0.98 (0.26, 3.35)    **Cis+Flu**          1.65 (0.43, 5.40)        1.64 (0.43, 5.31)    1.09 (0.28, 3.38)    0.37 (0.09, 1.36)       0.82 (0.29, 1.84)    0.83 (0.24, 2.29)    1.07 (0.35, 3.31)    1.33 (0.68, 2.23)
  **Cis+Metho- trexate**   0.25 (0.03, 1.52)   1.30 (0.20, 9.64)        0.52 (0.12, 2.50)    0.54 (0.11, 2.80)    0.67 (0.19, 2.37)    0.35 (0.04, 2.63)    0.60 (0.12, 3.05)    0.61 (0.19, 2.33)    **Cis+Metho- trexate**   1.00 (0.20, 5.27)    0.66 (0.13, 3.12)    0.23 (0.04, 1.18)       0.50 (0.13, 1.93)    0.50 (0.11, 2.14)    0.65 (0.13, 3.88)    0.82 (0.27, 2.47)
  **Cis+Pac**              0.25 (0.03, 1.54)   1.32 (0.18, 10.06)       0.53 (0.12, 2.62)    0.55 (0.10, 3.00)    0.68 (0.24, 1.92)    0.35 (0.05, 2.28)    0.60 (0.12, 3.19)    0.61 (0.19, 2.31)    1.00 (0.19, 5.12)        **Cis+Pac**          0.66 (0.13, 3.25)    0.23 (0.04, 1.24)       0.50 (0.13, 1.83)    0.50 (0.11, 2.16)    0.65 (0.14, 3.76)    0.82 (0.24, 2.66)
  **Cis+Vcr**              0.37 (0.05, 2.23)   1.98 (0.30, 14.48)       0.80 (0.18, 3.75)    0.82 (0.16, 4.30)    1.02 (0.30, 3.72)    0.53 (0.07, 4.00)    0.92 (0.20, 4.59)    0.92 (0.30, 3.52)    1.51 (0.32, 7.42)        1.52 (0.31, 7.63)    **Cis+Vcr**          0.35 (0.07, 1.77)       0.76 (0.20, 3.01)    0.76 (0.18, 3.36)    1.00 (0.21, 6.02)    1.24 (0.42, 3.75)
  **Epi**                  1.08 (0.15, 7.01)   5.65 (0.78, 44.07)       2.29 (0.48, 11.93)   2.36 (0.44, 13.23)   2.93 (0.79, 11.66)   1.51 (0.19, 12.41)   2.59 (0.51, 14.69)   2.67 (0.73, 11.15)   4.36 (0.85, 22.93)       4.29 (0.81, 24.10)   2.89 (0.56, 14.54)   **Epi**                 2.16 (0.52, 9.33)    2.15 (0.47, 10.39)   2.83 (0.57, 18.09)   3.55 (1.09, 12.39)
  **Flu**                  0.49 (0.08, 2.51)   2.61 (0.47, 16.14)       1.06 (0.30, 4.07)    1.09 (0.27, 4.68)    1.36 (0.64, 3.06)    0.70 (0.12, 4.12)    1.21 (0.31, 5.04)    1.22 (0.54, 3.46)    2.01 (0.52, 7.82)        2.00 (0.55, 7.60)    1.32 (0.33, 5.09)    0.46 (0.11, 1.94)       **Flu**              1.00 (0.37, 2.70)    1.29 (0.35, 6.33)    1.63 (0.76, 3.66)
  **Flu+MitoC**            0.49 (0.08, 2.81)   2.62 (0.42, 17.61)       1.06 (0.26, 4.63)    1.09 (0.23, 5.20)    1.35 (0.47, 3.99)    0.70 (0.10, 4.70)    1.21 (0.28, 5.56)    1.20 (0.44, 4.12)    1.99 (0.47, 8.80)        2.00 (0.46, 9.11)    1.32 (0.30, 5.52)    0.46 (0.10, 2.15)       1.00 (0.37, 2.70)    **Flu+MitoC**        1.31 (0.30, 7.13)    1.62 (0.63, 4.33)
  **Hyd**                  0.37 (0.04, 2.33)   2.02 (0.25, 14.72)       0.81 (0.14, 3.99)    0.83 (0.13, 4.42)    1.04 (0.26, 3.52)    0.53 (0.06, 3.70)    0.91 (0.15, 4.54)    0.93 (0.30, 2.83)    1.54 (0.26, 7.51)        1.53 (0.27, 7.27)    1.00 (0.17, 4.77)    0.35 (0.06, 1.77)       0.77 (0.16, 2.87)    0.76 (0.14, 3.30)    **Hyd**              1.24 (0.32, 3.95)
  **Placebo**              0.30 (0.06, 1.26)   1.59 (0.33, 8.26)        0.65 (0.23, 1.89)    0.67 (0.20, 2.24)    0.83 (0.46, 1.53)    0.43 (0.08, 2.30)    0.74 (0.24, 2.30)    0.75 (0.45, 1.48)    1.23 (0.40, 3.75)        1.22 (0.38, 4.11)    0.81 (0.27, 2.40)    **0.28 (0.08, 0.91)**   0.61 (0.27, 1.32)    0.62 (0.23, 1.58)    0.81 (0.25, 3.17)    **Placebo**

###### SUCRA value for each treatment under the outcomes of recurrence and distant metastasis

                                Outcome    
  ----------------------------- ---------- ----------
  **Ble + Cis + Ifo**           0.43       **0.83**
  **Ble + Cis + MitoC + Vbl**   0.24       0.20
  **Ble + Cis + Vbl**           0.21       0.56
  **Ble + Cis + Vcr**           0.18       0.54
  **Cis**                       0.52       0.41
  **Cis + Doc**                 **0.74**   **0.72**
  **Cis + Epi**                 0.20       0.50
  **Cis + Flu**                 0.68       0.48
  **Cis + Flu + Hyd**           0.67       \-
  **Cis + Ifo**                 **0.93**   \-
  **Cis + Ifo + Pac**           **0.91**   \-
  **Cis + Methotrexate**        0.38       0.23
  **Cis + Mitolactol**          0.47       \-
  **Cis + Pac**                 \-         0.23
  **Cis + Topotecan**           0.66       \-
  **Cis + Vcr**                 0.26       0.45
  **Epi**                       0.56       **0.88**
  **Flu**                       0.60       0.61
  **Flu + MitoC**               0.71       0.61
  **Hyd**                       0.42       0.45
  **Placebo**                   0.24       0.28

Distant metastasis {#s2_5}
------------------

The potencies of reducing the occurrence of distant metastasis were also estimated, and 15 interventions had data in contrast with placebo, shown in Table [7](#T7){ref-type="table"}. Only epirubicin (OR = 0.28, 95% CrI: 0.08-0.91) was significantly excellent in reducing the occurrence of distant metastasis. This was also affirmed in our SUCRA rank probability diagram, seen in Figure [2](#F2){ref-type="fig"} and Table [8](#T8){ref-type="table"}, since the SUCRA of epirubicin was 0.88, and the following two were bleomycin+cisplatin+ifosfamide (0.83), and cisplatin+docetaxel (0.73).

Inconsistency test {#s2_6}
------------------

The heat plots in Figures [3](#F3){ref-type="fig"}--[4](#F4){ref-type="fig"} provided a detailed assessment of the inconsistency in this NMA. It appeared that there was no significant inconsistency identified within the net heat plot. Publication bias was visually using the comparison-adjusted funnel plots (Figure [5](#F5){ref-type="fig"}). We found no significant asymmetry patterns in funnel plots, so we concluded there were no significant publication bias in the included studies.

![Netheat plots of inconsistency test for survival outcomes\
**(A)** 1-year overall survival (1-year OS); **(B)** 1-year recurrence-free survival (1year RFS); **(C)** 3-year OS; **(D)** 3-year RFS; **(E)** 5-year OS; **(F)** 5-year RFS.](oncotarget-08-49515-g003){#F3}

![Netheat plots of inconsistency test for recurrence and distant metastasis\
**(A)** recurrence; **(B)** distant metastasis.](oncotarget-08-49515-g004){#F4}

![Comparison adjusted funnel plots of publication bias test for recurrence and distant metastasis\
**(A)** recurrence; **(B)** distant metastasis.](oncotarget-08-49515-g005){#F5}

DISCUSSION {#s3}
==========

To appraise the efficacy of usual chemotherapies when combined with radiotherapy as concurrent, adjuvant, or neoadjuvant treatment to patients with cervical cancer after surgery, 39 RCTs or clinical trials covering 22 interventions were analyzed, in terms of OS, RFS, the incidence of recurrence, and distant metastasis, in this NMA. It is the first issue in this domain, which integrated both the direct evidence and the indirect comparison remedying the insufficiency of the traditional meta-analysis.

In accordance with results, the combination of two or three medicines with diverse functional mechanisms had better impact than mono-chemotherapy. On the basis of biochemical mechanisms, relevant agents can be classified into four types, drugs affecting the structure and function of DNA, drugs interfering protein synthesis and function, drugs intercalating DNA to interfere the transcription as well as drugs used for metabolism inhibition. Statistically, drugs affecting the structure and function of DNA, including cisplatin, ifosfamide, bleomycin, and mitomycin C, were the most common medication used in cervix cancer treatment, but the specific mechanism of agents differed from each other, such as cisplatin can form a cross link between the guanines in the DNA after dissociation with chlorine \[[@R54], [@R55]\] while ifosfamide lead DNA during S phase to shape into cross link, which inhibits the growth and reproduction of tumor cells \[[@R56]\]. Antimetabolites, fluorouracil and hydroxyurea involved, are referred to as the drugs influencing biosynthesis of nucleic acid as well as being vital to the cell growth and proliferation \[[@R57], [@R58]\]. By distinct mechanisms, the ultimate purpose of both agents is impeding the synthesis of DNA \[[@R59]--[@R61]\]. With respect to the drugs acting on the necessary proteins as tubulin and ribosome, paclitaxel and docetaxel upset the dynamic equilibrium between tubulin and its dimer, accelerate the assembling of tubulin and interfere with its disassembly, therefore stop the cell cycle at G~2~/M phase \[[@R62]--[@R64]\]. Epirubicin can insert the base pairs of DNA, limiting the activity of transcriptase to influence the synthesis of mRNA, especially in the S and M phase of cell cycle \[[@R65]\]. Thus, the combination of multiple drugs with distinctive anti-cancer mechanisms would tend to exhibit superior efficacy especially to reduce the drug resistance during the long term administration.

This NMA assessed the efficacy of 22 chemotherapeutic treatments, containing nearly all clinical regular prescription in the aspects of 1-year, 3-year, and 5-year OS and RFS, as well as the incidence of recurrence and distant metastasis. However, there is still insufficiency that cannot be denied. First, the inclusion trials were limited, and 13 strategies were emerged only once, the inherent error of which were brought in this NMA. Next, the dose and delivery method of each agents were not considered to be an impact factor, but these factors did have influence on their efficacy. The discrepancy on 5-year RFS of the trials between Pearcey and Wong might be caused by the dosage of cisplatin \[[@R39]\]. Moreover, though the FIGO stages of subjects were listed, there was no discrimination in the course of data analysis. Nevertheless, in the clinical practice, the conditions of patients had an important impact on treatment results, including periaortic and pelvic lymph node status, patient age, performance status, bilateral disease and clinical stage \[[@R66]\]. For instance it is evident that the tumor size had the direct relation to the occurrence of metastasis and recurrence \[[@R67], [@R68]\]. Therefore, more authentic trials are needed and on the basis of colossal data, the particular subgroup analysis can be performed.

Overall, in consideration of the results of this NMA, cisplatin+fluorouracil+hydroxyurea, cisplatin+ docetaxel and fluorouracil+mitomycin C, were outstanding in prolonging the length of OS, whilemitomycin C, cisplatin+fluorouracil+hydroxyurea and cisplatin+docetaxel had good performance in RFS. Integrating both OS and RFS data, cisplatin+fluorouracil+hydroxyurea and cisplatin+docetaxel were highly recommended as first tier chemotherapies based on their equally preferable performance in long term. The first three with excellent performance in reducing the recurrence were cisplatin+ifosfamide, cisplatin+ifosfamide+paclitaxel, and cisplatin+docetaxel, in contrast to epirubicin which were beneficial to the significant decrease of distant metastasis. However, it should be noted that the individual conditions of patient should be taken into account thoroughly in clinical application.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

To obtain the relevant trial data, we searched electronic database PubMed, Embase and Cochrane Library for RCTs and clinical trials, regardless of the diversity of language, with the following key terms and their synonyms combined, "cervix cancer", "radiotherapy", "surgery", and among "chemotherapy", "concurrent chemotherapy", "neoadjuvant chemotherapy", "adjuvant chemotherapy", and specific drugs, such as "cisplatin", "fluorouracil", "hydroxyurea" were included. Meanwhile, we also examined the reference lists of all the existed meta-analyses and systemic reviews, to guarantee the sample size of tested interventions. And all these work mentioned above were done by two reviewers individually.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

All the included trials must meet the listed criteria: (i) at least one of the involved interventions should be used to treat the cervix cancer of patients; (ii) the interventions could include concurrent chemotherapy, neoadjuvant chemotherapy, and adjuvant chemotherapy, but should be combined with radiotherapy and after surgery, while the strategy of radiotherapy and surgery were no limitations; (iii) the overall survival (OS) or the recurrence-free survival (RFS) should be compared between two interventions or interventions and placebo. Besides, although some trials satisfied the inclusion conditions, since they carried out between different methods of administration of the identical drug or the intervention they investigated which cannot form a loop, they were still excluded eventually. The trials included should also meet PRISMA guidelines. According to these criteria, two reviewers screened titles and abstracts of all retrieved articles, and the full texts would be examined respectively when necessary. And any arguments would be solved under discussion by the panel.

Outcome measurements and data extraction {#s4_3}
----------------------------------------

The basic features of this study, including author, year of publication, country, and the efficacy outcomes, were extracted from each eligible trial \[[@R69]\]. To assess the prognosis of chemotherapy aiming to cervix cancer, OS and RFS are the common outcomes. And quoting the interpretation from the NCI, OS indicates the length of time from the start of the chemotherapy for the cervix cancer, that patients diagnosed with the disease are still alive; and RFS means the length of time during and after the chemotherapy of the cervix cancer, that a patient lives without the diagnosed cancer. Except for the data given directly, the outcomes can also be extracted from the OS and RFS curves, the cumulative percentage versus time after chemotherapy administration. The incidence of recurrence and distant metastases were also evaluated as efficacy predictors.

Statistical analysis {#s4_4}
--------------------

Based on the connection among treatments, four network plots on recurrence, distant metastasis, OS and RFS were drawn. The heterogeneity of fixed-effects model among each study effect was calculated through Cochran\'s Q and I squared statistic, which were presented in the net heat plots \[[@R70], [@R71]\]. Generally, if *P~h~* \< 0.05 or *I*^2^ \> 50%, it implied that a significant heterogeneity was existed, and then the fixed-effects model would be replaced by the random-effects model.

STATA 12.0 software and WinBUGS software were used for, which showed us the combination of direct and indirect evidence. In this NMA, we synthesized the direct and indirect evidence on 1-year, 3-year, 5-year OS and RFS, recurrence and distant metastasis. HR or OR with their 95% credible intervals (CrIs) were applied to evaluate the relative efficacy for specific comparison. To sort the chemotherapies according to their efficacies on recurrence and distant metastasis, the surface under the cumulative ranking curve (SUCRA) was applied, cumulating the percentages of each intervention with assuming the best, the second best and so on. And then, the optimal treatment would have the highest cumulative probability \[[@R72]\]. Furthermore, the heat plots for each outcome were performed to reflect the contribution of direct evidence to the network comparison and their inconsistency. Moreover, the publication bias on recurrence and distant metastasis were considered through the funnel plots, standard error of effect size versus the effect size centered at comparison-specific pooled effect.
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